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Abstract 
 
A large percentage of human cancers show mutations in RAS, a critical activator of the 
mitogen activated protein kinase (MAPK) signaling cascade that has been well documented 
for its role in driving tumorigenesis. While there have been numerous attempts to inhibit 
RAS signaling, efforts have largely been unsuccessful. The major reason leading to the 
lack of success is the small size of the RAS protein, which prevents the discovery of 
adequate binding sites for small molecules. While directly inhibiting RAS has not been 
achieved except in isolated cases, there has been much better success at inhibiting 
downstream effectors of RAS. Inhibition of downstream effectors have focused on MAPK 
pathway kinases RAF, MEK and ERK. Additionally, inhibition of PI3K as well as the 
human growth factor receptors (HERs) have been moderately successful. However, 
resistance and adaptive signaling in response to therapy is prevalent. A new trend of 
combination therapies is emerging within the field, allowing effective inhibition of 
multiple proteins in ways that reduce the ability of tumor cells to escape inhibition. 
The goal of this dissertation is to delineate downstream effectors that are effective in 
blocking RAS signaling when combined with another kinase inhibitor and evaluate 
efficacy of these combination strategies. Focus was placed on developing novel strategies 
for the treatment of patients diagnosed with KRAS-activated pancreatic or colorectal 
cancer, an isoform of the RAS oncogene. These cancers show high mutation rates in 
KRAS: up to 90% in pancreatic cancer and 30-50% in colorectal cancer. The high mutation 
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rate and lack of effective therapies for patients diagnosed KRAS-mutant disease is a critical 
unmet need. 
These two chapters approach the problem in different ways. In Chapter 2, which explores 
co-inhibition of MEK and CDK4/6, a screen was employed to find the most responsive 
cancer cell line models of a panel. This study identified two pancreatic cancer models, 
L3.6pl and UM59, that exhibited the highest response to treatment. In these models, it was 
found that COX-2 expression was higher than in those that did not respond as well. These 
findings identify a potential biomarker that could have implications for current and future 
clinical trials evaluating this treatment strategy. 
Chapter 3 evaluates the activity of a rationally designed molecule that inhibits PI3K and 
EGFR. These are two prominent proteins central to growth signaling in the cell that 
participate with RAS for malignant growth. The activity of MTX-211 was screened for 
activity on the NCI-60 panel, a curated collection of cancer cell line models from different 
tissues. From this screen, it emerged that MTX-211 was most effective in colorectal cancer 
models and in models with a PIK3CA mutation. Further evaluation of MTX-211 identified 
MEK, a downstream signaling effector of RAS, as an ideal combination partner. Inhibition 
of cancer cells with a MEK inhibitor activates EGFR and PI3K signaling, which MTX-211 
can block. This is a novel combination strategy that is effective in targeting adaptive 
signaling that emerges from single agent MEK inhibition and causes apoptosis in treated 
xv 
 
cells. It was further found that MTX-211 was effective as a single agent and in combination 
with a MEK inhibitor in several animal studies of tumor-bearing mice. 
 
 1 
 
 
 
 
Chapter 1: Introduction 
 
RAS BIOLOGY 
A large percentage of human cancers show mutations in the protein RAS, a critical 
activator of the mitogen activated protein kinase (MAPK) signaling cascade that has been 
well documented for its role in driving tumorigenesis. Mutations in RAS regulators such 
as SPRED1 and neurofibromin also contribute to cancer. Germline mutations that lead to 
overactive RAS/MAPK signaling contribute to “RASopathies,” developmental conditions 
which exist in over 400,000 people in the United States (Simanshu et al., 2017). RAS 
proteins function as molecular switches that cycle between inactive GDP-bound and active 
GTP-bound states. The exchange of GDP for GTP and vice versa is promoted by guanine 
Figure 1.1: RAS-GDP  RAS-GTP cycle. 
RAS proteins cycle between an inactive GDP-bound and an active GTP-bound state. These transitions are 
facilitated by the binding of GEFs (NF1/SOS1/many others) and GAPs. The presence of RAS-GTP activates 
many signaling pathways implicated in cancer, and oncogenic mutations in RAS cripple the GTPase activity 
and the ability to transition into the GDP-bound state. 
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nucleotide exchange-factors (GEFs) and GTPase-activating proteins (GAPs), respectively, 
shown in Figure 1.1 (Cherfils and Zeghouf, 2013). GEFs and GAPs are large multi-domain 
structures with varied interactions with other proteins, lipids and regulatory molecules that 
influence the activation of RAS (Bos et al., 2007). These varied signaling inputs to both 
GEFs/GAPs and RAS contribute to a complex network of growth signaling. Translocation 
to the plasma membrane governs RAS activation and modulation by GEFs and GAPs, as 
well as interaction of RAS with effectors. The RAF kinase is activated by translocation to 
the membrane, wherein its N-terminal RAS-binding domain (RBD) binds to RAS-GTP. 
This interaction leads to conformational changes that lead to phosphorylation of RAF and 
stimulate the serine/threonine kinase activity that sequentially phosphorylates and activates 
MEK and in turn MAPK, or ERK (extracellular signal regulated kinase, shown in Figure 
1.2) (Wan et al., 2004). Activation of other RAS effectors also occurs by recruitment to the 
plasma membrane, such as certain phosphoinositol 3-kinase (PI3K) isoforms requiring 
myristoylation (Simanshu et al., 2017). Furthermore, activation and localization of RAS 
and effectors can be modulated by local lipid composition of the plasma membrane, 
Figure 1.2: The canonical MAPK signaling pathway. The MAPK signaling pathway, in its simplest form, 
is initiated by growth factors/ligand binding the extracellular domain of HER1/2/3, inducing dimerization and 
the sequence of events leading to sequential activation of RAS-RAF-MEK-ERK. 
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drawing attention to the role of the plasma membrane in RAS biology and signaling (Zhou 
and Hancock, 2015; Zhou et al., 2017). 
RAS is ubiquitously expressed in all tissue in three isoforms: NRAS, HRAS and KRAS. 
While all three isoforms are concurrently expressed in human tissue, tissue specific 
disparities in isoform expression exist (Fiorucci and Hall, 1988; Furth et al., 1987). 
Approximately 30% of all human cancer has a mutation in RAS, with KRAS being the 
most frequently mutated RAS isoform at 22%, followed by NRAS (8%) and HRAS (2%) 
(Prior et al., 2012). In colorectal cancer, 30 – 50% of cases have a mutation in KRAS 
(Vaughn et al., 2011) while for pancreatic cancer the mutation rate has been extensively 
reported to be >90% (Biankin et al., 2012; Witkiewicz et al., 2015b). Notably, KRAS is 
the most frequently mutated oncogene of either cancer subtype (Thomas et al., 2007). 
KRAS was originally identified in the Kirsten sarcoma virus DNA and was one of the first 
oncogenes discovered through studies involving the ability of viral DNA and DNA 
fragments to transform cells (Tsuchida et al., 1982; Tsuchida and Uesugi, 1981). Since 
then, the role of RAS in cancer biology has been comprehensively studied. However, 
despite the field’s best efforts, RAS has remained undruggable since it was discovered.  
Inhibiting RAS Signaling 
As summarized below some of the key approaches to target deregulated RAS signaling 
have included direct small molecule inhibition of RAS, blocking RAS membrane 
association and targeting downstream effectors targeting of synthetic lethal interactions 
(Cox et al., 2014; Lu et al., 2016; Papke and Der, 2017). 
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Inhibiting membrane association of RAS 
Early efforts to target RAS signaling focused on inhibiting membrane association of the 
small GTPase, which is a critical step for signaling. The addition of a farnesyl isoprenoid 
lipid modification at RAS C-terminal CAAX motifs is one posttranslational modification 
controlling membrane association that was an early target for drug discovery (Cox et al., 
2015). Research into this area led to the development of farnesyltransferase inhibitors 
(FTIs). However, FTIs categorically failed to inhibit RAS signaling, not because of a lack 
of target potency, but because cells responded with alternative prenylation by 
geranylgeranyltransferases (FTI induced alternative prenylation) (Rowell et al., 1997; 
Whyte et al., 1997). Two clinical candidates, lonafarnib and tipifarnib, advanced to phase 
III clinical trials but showed no efficacy in lung, pancreatic and colorectal cancer (Papke 
and Der, 2017). 
Direct inhibition of RAS 
There have been some efforts delving into direct inhibition of RAS by interfering with 
GDP/GTP binding. Some of these attempts have only met with limited success, largely 
because of the difficulty in antagonizing the picomolar affinity of RAS for GTP in a cellular 
context with millimolar concentrations of GTP (Cox et al., 2014). Other efforts have failed 
in part due to the small size of the GTPase, which limits the amount of available binding 
pockets other than the nucleotide binding site. Additional attempts have focused on 
disruption with either the interaction domain that binds RAF (Shima et al., 2013) or a SOS 
interaction domain that stimulates the exchange of GDP for GTP (Maurer et al., 2012; 
Papke and Der, 2017). Protein-protein interactions have been found to be largely 
intractable as druggable targets though, given the small size of RAS. 
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One development is rigosertib (Onconova Therapeutics), a small molecule RAS mimetic 
(Athuluri-Divakar et al., 2016). One thing in common between many RAS effectors is the 
presence of a RAS binding domain (RBD), which binds to the switch region of RAS and 
leads to the activation event. Rigosertib has been shown to bind to the RBDs of RAF, Ras-
GDS and PI3Ks, which competes with RAS for binding to effectors. This disruption in 
protein-protein interactions therefore leads to an inability of RAS to activate effector 
pathways. Rigosertib is currently being evaluated in a Phase 3 cohort of higher-risk 
myelodysplastic syndromes (MDS) who have progressed on prior hypomethylating agent 
(HMA) therapy (Onconova, 2018). 
Another attempt to target KRAS is specific for the G12C mutation. Compounds have been 
designed that covalently bind specifically to this mutant form of KRAS, which is 
predominant in lung cancer, although these inhibitors have met with obstacles in preclinical 
studies (Janes et al., 2018; Ostrem et al., 2013). Also, this approach unfortunately caters 
only to the G12C mutant form due to the formation of a covalent bond. The G12C mutation 
is also one of the RAS mutations with the lowest frequency, limiting the therapeutic impact 
of this approach. Other attempts to directly inhibit other mutations in RAS are ongoing, 
with efforts by the NCI Ras initiative leading the field. 
Synthetic lethal approaches to RASmt cancer 
Another approach to target RAS signaling relies on the concept of synthetic lethality. A 
synthetic lethal interaction, in this context, would be a gene that is required for survival of 
RASmt cancer that is not required for a normal RAS wild type cell. In other words, a cell 
that does not normally rely on a gene may become dependent on this gene/pathway for 
survival in a RASmt context, and when removed or inhibited, the cell will die. A weakness 
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of this approach is the use of RNAi-based screens with RASmt/RASwt paired isogenic lines 
to determine which genes are synthetic lethal. In order to produce matched isogenic lines, 
stable deletion of RAS is required, which in itself is a potent cellular stimulus that would 
give rise to adaptive signaling in the cells that survive (Papke and Der, 2017). This concept 
has generated a lot of interest but has failed to deliver on high expectations, partly due to 
the inability to replicate results. Part of this may also be context-specific, wherein synthetic 
lethality is exclusive to a particular context, metabolic state or site-specific cancer.  
One target identified as being synthetic lethal in KRASmt NSCLC is CDK4, a protein 
critical for progression of the cell cycle from G1 to S phase (Mao et al., 2014; Puyol et al., 
2010). In these studies, either genetic ablation of CDK4 (Puyol et al., 2010) or targeted 
delivery of CDK4 siRNA (Mao et al., 2014) to KRASmt tumors led to senescence and 
prevented tumor progression. Recently, pharmacologic inhibition of CDK4 and CDK6 has 
been made possible with the discovery of small molecule inhibitors palbociclib (Pfizer, 
2015), ribociclib (Eli Lilly, 2017) and abemaciclib (Novartis, 2017). In Chapter 2, a 
therapeutic approach to co-targeting of CDK4/6 and MEK is covered, partly based on these 
findings. The convergence of synthetic lethality research that identifies potential targets in 
the field and the ability to target effector signaling with emerging agents is a promising 
application of preclinical research in this area. 
Targeting RASmt signaling through effector pathways 
Targeting downstream signaling or effector pathways has been one of the most successful 
attempts at attenuating RASmt signaling. RAS signaling is multifaceted and significant 
attention has been afforded to inhibiting the two main downstream effector pathways of 
RAS: the RAF-MEK-ERK signaling pathway as well as the PI3K-AKT signaling axis 
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(Castellano and Downward, 2011; Ryan et al., 2015; Wong et al., 2010). Most of these 
effectors have been the target of kinase inhibitor development, with numerous inhibitors 
ranging from preclinical candidates to FDA approved small molecules having been 
developed. The field generally recognizes that RAF-MEK-ERK downstream pathway is 
critical for progression of RASmt tumors (Ryan et al., 2015). Part of the reason for the 
limited success of these kinase inhibitors in cancer is the presence of ERK-mediated 
regulatory feedback loops that normally limit pathway output. In a wild type RAS context, 
increased ERK activity leads to phosphorylation-based feedback inhibition of multiple 
kinases to dampen flux of the pathway (Lake et al., 2016). In response to inhibition of 
upstream kinases, ERK activity is diminished, which can lead to paradoxical activation of 
the pathway due to the loss of feedback inhibition by ERK. 
MAPK signaling has been shown to lead to phosphorylation of epidermal growth factor 
receptor (EGFR) at Threonine 669 (T669) (Li et al., 2008b). While the physiological 
consequences of this phosphorylation site are somewhat disputed (Brewer et al., 2009; 
Heisermann et al., 1990; Kovacs et al., 2015; Welsh et al., 1991), it is a putative regulatory 
site of EGFR. Studies have shown that MEK inhibition can lead to the loss of this inhibitory 
threonine phosphorylation, thereby hyperactivating HER3/ERBB3, which increases flux 
through the PI3K/AKT pathway in KRASwt cells and the MAPK pathway in KRASmt cells 
(Turke et al., 2012b). This introduces a viable therapeutic approach to this resistance, 
wherein targeting the RTKs responsible for resistance can result in synergistic activity 
(Chapter 3). 
In addition to regulatory feedback at T669 of EGFR, intrinsic resistance to MEK inhibitors 
has been attributed to transcriptional activation of receptor tyrosine kinases (RTKs) HER2 
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and HER3. This leads to a subsequent increase in heterodimeric complexes such as 
EGFR/HER3 and HER2/HER3 which can lead to increased MEK-ERK and PI3K-AKT 
signaling (Ebi et al., 2011; Kitai et al., 2016; Sun et al., 2014). Moreover, several other 
RTKs have shown induction in response to MEK inhibition: PDGFR, VEGFR2, CSFR1, 
DDR1/2 and AXL, highlighting the complexity of feedback networks impacted by 
pharmacologic manipulation of ERK activation levels (Duncan et al., 2012). In addition to 
feedback inhibition of EGFR, ERK also phosphorylates and plays similar roles in inhibiting 
MEK and RAF (Lake et al., 2016; Ueki et al., 1994; Wartmann et al., 1997). ERK also has 
inhibitory effects on SOS1 (disrupting interaction with GRB2), DUSP6 stability (ERK1/2 
phosphatase) and the scaffold protein SPRY (disrupts SOS1 interaction with GRB2 as well, 
Figure 1.3) (Corcoran et al., 2012; Red Brewer et al., 2009; Turke et al., 2012b; Zhang et 
al., 2010).  
The dynamic regulatory feedback mechanisms in place in the MAPK pathway is 
exacerbated by the numerous effector pathways of RAS, of which the canonical RAF-
mediated MAPK signaling is only one. Another important pathway that carries RAS 
oncogenic signaling is the phosphatidylinositol 3-kinase (PI3K) pathway and receptor 
tyrosine kinases (RTKs) involved in activation of RAS. 
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Figure 1.3: Regulation of ERK activation and ERK feedback inhibition mechanisms. ERK activation sets 
into motion several regulation events designed to inhibit basal tone of the pathway. ERK phosphorylates and 
inhibits EGFR in the juxtamembrane region at threonine 669. It also phosphorylates RAF and MEK, which 
limits activation of these kinases. In addition to phosphorylation-based regulation events, ERK activation leads 
to transcription of SPRY which disrupts the GRB2/SOS1 interaction, limiting RAS activation. It also leads to 
upregulation of DUSP6 expression, an ERK phosphatase, which is additionally activated by direct 
phosphorylation by ERK. Inhibition of ERK via any node in this pathway will reduce this feedback activation, 
leading to relief of feedback activation an and increase in basal tone. 
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RTKs involved in RAS activation 
Broadly speaking, the human epidermal growth factor receptor (HER) family activates 
many different growth pathways that are Ras-dependent as well as independent. There is 
significant overlap in some of these pathways as covered with the Ras-PI3K crosstalk. The 
HER family is composed of four members: HER1 (EGFR), HER2, HER3 and HER4. Of 
these, HER4 has not been shown to significantly contribute to oncogenesis, and of the 
remaining, HER3 does not have catalytic activity but contributes to the 
autophosphorylation of the other members when dimerized.  
The general structure of this family is comprised of an extracellular domain, a 
transmembrane domain and an intracellular domain containing the C-terminal tail and the 
catalytic domain (Sergina and Moasser, 2007). Dimerization, either through hetero- or 
homodimerization, is required for activation of the receptors through transphosphorylation 
of the C-terminus. The dimerization events are controlled by extracellular ligands that 
induce conformational changes in the receptors leading to dimerization. When no ligand is 
bound, the extracellular dimerization domain is involved in an intra-molecular interaction 
that keeps it inactivated. Ligand binding induces a conformational change that exposes this 
dimerization interface for inter-receptor interactions. Upon binding of the extracellular 
domains, the intracellular domain of these proteins simultaneously engage in 
transphosphorylation events, leading to activation and recruitment of downstream effectors 
that recognize these tyrosine phosphorylations (also known as docking sites for SH2 and 
PTB domains, Figure 1.4) (Burgess et al., 2003). In this regard, HER2 is unique, as the 
extracellular domain exists in a conformation similar to the ligand-bound states of other 
HER extracellular domains. Therefore, no ligand exists for the activation of HER2 and 
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activation of this member is likely governed by factors differing from the other family 
members (Garrett et al., 2003). 
A hierarchical network of inter-receptor interactions determines the potency of the homo- 
and heterodimer pairs, with heterodimers being more potent than homodimers. Of these, 
the HER2-HER3 interaction is the most active (Tzahar et al., 1996). Selectivity for 
downstream interaction pathways is controlled by many factors including the amount of 
interaction motifs for factors such as Grb2, PI3K, STAT5, as well as phosphorylation 
kinetics of various tyrosine residues that are correlated with interaction partner preferences 
(Schulze et al., 2005). In other words, this selectivity is controlled by consensus binding 
sequences that are phosphorylation dependent as well as independent (Jones et al., 2006). 
The interactomes of each HER family member reveal patterns of partner selection that are 
dynamic, not static, as studies examining the genome set of SH2 and PTB domains and 
their interactions with HER family peptide fragments find differences in binding locations 
in comparison to known interaction sequences. The recruitment sites on HER2 were found 
to be the most promiscuous to diverse domains and higher concentrations of EGFR and 
HER2 led to increased promiscuity of these interactions with the SH2 and PTB domains. 
The authors hypothesized that this contributes to the high oncogenic activity of these 
oncogenes, especially considering the frequency of gene amplification occurring within the 
gene loci encoding the HER family members (Garrett et al., 2003; Jones et al., 2006; 
Slamon et al., 1987). Furthermore, HER3 is characterized by many p85 binding sites, 
consistent with reports implicating HER3 in activation of the PI3K-MTOR signaling axis 
both basally and in resistance to tyrosine kinase inhibitor therapy (Sergina et al., 2007). 
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Each HER family member additionally has a Grb2 docking site, consistent with the ability 
to activate the Ras-ERK pathway (Sergina and Moasser, 2007).  
RAF 
RAF is a dual serine/threonine kinase and the family is comprised of three isoforms: 
ARAF, BRAF and CRAF. Of these, BRAF has the highest basal activity, activates MEK 
more potently than the others, and is the most frequently activated isoform in human cancer 
(Fiskus and Mitsiades, 2016). RAF activation occurs when Ras-GTP binds to the RBD of 
RAF (N-terminal region). Conformational changes and recruitment to the plasma 
membrane caused by this interaction induces RAF phosphorylation, which facilitates the 
kinase activity of RAF (Figure 1.4) (Wan et al., 2004). The majority of mutations in BRAF 
occur in the activation segment, flanking regions, and the negatively charged regulatory 
region (glycine-rich P loop of the N lobe). The negative charge of phosphorylation disrupts 
the hydrophobic interaction between the activation segment (T599 and S602) and the P 
loop, thereby activating the enzyme. The most common mutation in BRAF is the valine to 
glutamate (V600E) amino acid substitution, which occurs in the activation segment, 
disrupting the hydrophobic interaction keeping the enzyme in an inactive conformation. 
This mutation therefore explains the potent oncogenic activity of BRAFV600E (Fiskus and 
Mitsiades, 2016; Wan et al., 2004). Vemurafenib was the first FDA approved BRAF 
inhibitor for the treatment of BRAF mutant melanoma (Bollag et al., 2012). Since then, 
two additional BRAF inhibitors have been approved for treatment of this disease in 
combination with a MEK inhibitor, namely dabrafenib (co-administered with trametinib) 
and encorafenib (co-administered with binimetinib) (FDA, 2018). These are listed in Table 
1.1. Vemurafenib and dabrafenib are approved for the treatment of BRAF-mutant 
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malignant melanoma based on progression-free and overall survival, and rapid tumor 
regression is observed in 70-80% of patients receiving therapy (Ryan et al., 2015). 
However, resistance to these inhibitors occurs rapidly in melanoma, colorectal, lung and 
thyroid cancers. Mechanisms of resistance to these inhibitors includes RTK activation, 
NRAS mutation, NF1 inactivation (a GTPase-activating protein [GAP] of RAS) (Kidger 
et al., 2018; Nissan et al., 2013; Simanshu et al., 2017) and increased RAF activity 
(truncation or increased expression) (Lidsky et al., 2014; Nazarian et al., 2010). These all 
lead to increased MAPK flux and activation of ERK. Considering that 80% suppression of 
phosphorylation of ERK is required to observe clinical activity, these resistance 
mechanisms limit the utility of these inhibitors as therapies in patients (Bollag et al., 2010).  
Furthermore, despite the activity of vemurafenib and dabrafenib in patients diagnosed with 
BRAF-mutant disease, in RAS-mutant patients, cancer growth stimulation occurs when 
treated with these agents, increasing ERK activity (Callahan et al., 2012; Oberholzer et al., 
2012). In the RAS-mutant context, the drug-inactivated form of BRAF forms a heterodimer 
with CRAF, which causes RAS-induced CRAF activation and flux through the pathway. 
This has been termed paradoxical ERK activation with BRAF inhibitors, and third-
generation BRAF inhibitors were designed with this shortfall in mind and are termed 
“paradox breakers” (Ryan et al., 2015). More information on the nuances of RAF inhibitors 
are covered by Karoulia et al (Karoulia et al., 2016). PLX8394 (Plexxikon) was one of the 
first inhibitors of this third generation, with binding affinity for BRAF and CRAF as well 
as activity in RAS-mutant and vemurafenib resistant cells (Basile et al., 2014). More 
inhibitors that target the paradoxical activation are in development, such as LY3009120, a 
panRAF and dimer inhibitor by Eli Lilly (Vakana et al., 2017). This inhibitor has also 
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shown promising preclinical activity in KRASmt/BRAFmt colorectal cancer patient derived 
xenograft (PDX) models. 
RAF inhibitor Target Company Clinical Phase 
Vemurafenib 
(PLX4032) BRAF
V600E, BRAFWT, CRAF Plexxikon/Genentech FDA approved 
Dabrafenib 
(GSK2118436) BRAF
V600E, BRAFWT, CRAF Novartis/GlaxoSmithKline FDA approved 
Encorafenib 
(LGX818) BRAF
V600E Array BioPharma FDA approved 
Sorafenib 
BRAFV600E, BRAFWT, CRAF, RET, 
c-KIT, Flt-3, VEGFR1, VEGFR2, 
FGFR1, p38 
Bayer FDA approved 
LY3009120 panRAF Eli Lilly and Company Pre- 
PLX4720 BRAFV600E, BRAFWT, CRAF Plexxikon Pre- 
SB-590885 BRAFV600E, BRAFWT, CRAF GlaxoSmithKline Pre- 
GDC-0879 BRAFV600E, BRAFWT, CRAF Genentech Pre- 
Regorafenib 
BRAFV600E, BRAFWT, CRAF, RET, 
c-KIT, TIE2, VEGFR1, VEGFR2, 
VEGFR3. FGFR1, PDGFR-β 
Bayer III 
XL281 BRAFV600E, BRAFWT, CRAF Exelixis I/II 
RAF265 BRAF
V600E, BRAFWT, CRAF, c-
KIT, VEGFR2, PDGFR-β Novartis II 
ARQ736 BRAFV600E, BRAFWT, CRAF ArQule I 
Table 1.1: RAF clinical inhibitors. Adapted from (Rahman et al., 2014; Ryan et al., 2015). 
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Figure 1.4: A snapshot of MAPK and PI3K-AKT signaling axes. Included in this figure is the MAPK 
signaling pathway shown on the left, with the addition of PI3K (p85-p110) activation and the sequence of 
events leading to AKT and MTOR activation. Briefly, PI3K phosphorylates and converts PIP2  PIP3 (a 
process which PTEN, a tumor suppressor, reverses), which recruits PDK1 to the plasma membrane, leading 
to phosphorylation of AKT on T308. AKT activation leads to mammalian target of rapamycin (MTOR) 
activation which phosphorylates AKT on S473 to increase its activity. MTOR is involved in facilitating cap-
dependent translation and additionally leads to activation of S6 and programmed cell death 4 (PDCD4), a 
tumor suppressor in facilitating cap-dependent translation and additionally leads to activation of S6 and 
programmed cell death 4 (PDCD4), a tumor suppressor. 
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MEK 
MEK directly phosphorylates ERK and is the closest upstream kinase to RAS, which 
initially was part of the rationale for the development of MEK inhibitors for therapeutic 
intervention. MEK1 and MEK2 are highly homologous kinases and are comprised of a 
kinase domain, ERK-docking region, a negative regulatory region, a nuclear export 
sequence and a proline-rich insert (Zhao and Adjei, 2014). What makes these kinases 
favorable to therapeutic intervention is the presence of a unique pocket structure adjacent 
but separate to the ATP-binding site, which was discovered by crystallography of MEK 
bound to highly selective agents (Ohren et al., 2004). Inhibition within this pocket locks 
unphosphorylated MEK into a catalytically inactive state. The presence of this unique 
pocket leads therapeutic interventions to be highly specific for MEK, bypassing the pitfall 
of ATP-competitive inhibitors that are less selective.  
The first MEK inhibitor to enter clinical trials was CI-1040, which is the first reported 
orally active agent in this target class (Sebolt-Leopold et al., 1999). It is a potent inhibitor 
of MEK1/2 (17 nM IC50 against MEK1). Similar to the MEK inhibitors discovered prior to 
it, PD98059 and U0126, CI-1040 inhibits MEK1/2 in a non-ATP/non-ERK1/2 competitive 
way (Allen et al., 2003; Frémin and Meloche, 2010). While the clinical trials with CI-1040 
failed to advance, this prototype MEK inhibitor helped set the field for future MEK 
inhibitors. 
Further, while development of MEK inhibitors began in the early 1990s, the first MEK 
inhibitor to gain FDA approval was trametinib in 2013 for the treatment of BRAFmt 
melanoma (cobimetinib was second in 2015). Despite their potent in vitro activity against 
KRAS mutant tumor cells (Wee et al., 2009), in vivo activity of MEK inhibitors as single 
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agents has been disappointing due to the development of resistance (Little et al., 2011; 
Poulikakos and Solit, 2011; Turke et al., 2012b; Wee et al., 2009). Table 1.2 shows some 
of the current MEK inhibitors in the field. 
MEK inhibitor Target Company Clinical Phase 
MEK162/binimetinib MEK1/2 Array BioPharma  FDA approved 
Cobimetinib MEK1/2 Exelixis/Genentech FDA approved 
Trametinib MEK1/2 Novartis FDA approved 
PD-0325901 MEK1/2 Pfizer Phase II 
CI-1040 MEK1/2 Pfizer Terminated 
Selumetinib MEK1/2 AstraZeneca Phase III 
AZD8330 MEK1/2 AstraZeneca Phase I 
TAK-733 MEK1/2 Millenium Pharmaceutical/Takeda Phase I 
GDC-0623 MEK1/2 Genentech Phase I 
Refametinib MEK1/2 Ardea Biosciences/Bayer Phase II 
Pimasertib MEK1/2 Merck and co. Phase II 
RO4987655 MEK1 Hoffman-La Roche Phase I 
RO5126766 RAF/MEK1/2 Hoffman-La Roche Phase I 
WX-554 MEK1/2 Wilex, AG. Germany Terminated 
HL-085 MEK1 Binjiang Pharma Phase I 
Table 1.2: MEK clinical candidates. Adapted in part from (Cheng and Tian, 2017; Ryan et al., 2015; Zhao 
and Adjei, 2014). 
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Through analysis of 17 unique MEK mutants from the CBioPortal genomic database of 
human cancer, Gao et al (Gao et al., 2018) classify these MEK mutations into Class 1/2/3, 
which drive ERK signaling and are sensitive to feedback inhibition in different ways 
(described in detail in Figure 1.5). The implications of these new mutations carve a new 
niche for ATP-competitive MEK inhibitors, as allosteric inhibitors are ineffective at 
Figure 1.5: Mapping the path to ERK activation in the context of MEK mutations. Sequential RAS-RAF-
MEK-ERK activation defines the wild type context. Class I MEK mutants behave in a similar manner to wild 
type MEK which is completely reliant on RAF for activation. Class I MEK mutants are sensitive to ERK 
mediated feedback inhibition, with a decrease in upstream signaling leading to a reduction in MEK activation. 
Class 2 MEK mutants retain activity in the absence of RAF but are stimulated in the presence of RAF. For this 
reason, class 2 mutants have been termed “RAF-regulated,” or dependent on RAF for only a portion of their 
activity. ERK feedback inhibition therefore only partially reduces the activity of Class 2 mutants. Class 3, or 
“RAF-independent,” MEK mutants have a deletion in the 98-104 amino acid region that eliminates binding and 
reliance on RAF for activation. Gao et al posit that this region is a potent negative regulator of MEK activity, 
and its absence drives Class 3 mutants to constitutive activity and the ability to auto-phosphorylate in cis. Since 
this class does not rely on RAF for activation, it is also immune to feedback inhibition, thereby driving higher 
basal levels of ERK activation than the other two classes. Furthermore, allosteric MEK inhibitors show 
significantly reduced potency against Class 3 mutants compared to Class 1 and 2 mutants, while an ATP-
competitive MEK inhibitor (MAP855) showed similar potencies against all MEK mutants. It is thought that the 
permanent active conformation of Class 3 mutants negatively affects the ability of allosteric inhibitors to bind, 
since they preferentially bind the inactive conformation. 
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targeting the Class III MEK mutations, which are characterized by insensitivity to RAF 
feedback inhibition and can drive ERK activation autonomously. The authors describe an 
ATP-competitive inhibitor from Novartis that inhibits all three classes of MEK mutations 
(MAP855). It remains to be seen whether ATP-competitive MEK inhibitors can replace 
the highly selective allosteric MEK inhibitors or whether they are reserved for cases in 
which resistance is developed. 
ERK 
ERK1/2 are two dual serine/threonine kinases with 85% identical sequences and function. 
They are activated by dual phosphorylation on threonine and tyrosine residues in the 
activation loop by MEK1/2, which stimulates nuclear translocation. They have a broad 
range of target substrates, such as phospholipases, cytoskeleton proteins and transcription 
factors. They are activated by serum, growth factors, phorbol esters as well as G protein 
coupled receptor (GPCR) ligands, cytokines, microtubule disorganization and osmotic 
stress (Figure 1.4) (Roux and Blenis, 2004). 
The utility of RAF and MEK inhibitors has been limited by emergence of resistance and 
compensatory activation of the pathway. While the reactivation of ERK signaling in 
response to RAF and MEK inhibitors is the basis for their combination in new clinical 
trials, novel pathway inhibitors are still needed. 
Recent studies have focused on development and comparative evaluation of ERK 
inhibitors. One of the first ERK inhibitors that advanced to the clinic, SCH772984, is a 
highly selective, ATP-competitive inhibitor of ERK1/2 (4 and 1 nM IC50, respectively). 
SCH772984 inhibits both ERK kinase activity as well as MEK-mediated phosphorylation 
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of ERK, as the compound was designed to bind to unphosphorylated, or inactive, ERK2 
(Morris et al., 2013). Interestingly, <50% of RASmt cell lines responded to therapy with 
SCH882984 and <20% of BRAFwt and RASwt responded. In BRAFmt cell lines in which 
resistance emerged to vemurafenib or trametinib due to RAS or MEK1 mutations, 
SCH722984 had demonstrable activity. These data prompted the first ERK inhibitor 
clinical trials for patients that initially responded to trametinib or vemurafenib but 
developed resistance.  
Furthermore, the combination of ERK and RAF inhibition is warranted for the same reason 
as RAF and MEK, due to reactivation of ERK signaling (Nissan et al., 2013). In fact, 
SCH772984 and other ERK inhibitors that work in a similar manner might function better 
ERK inhibitor Target Company Clinical Phase 
SCH772984 ERK1/2 Merck Pre-clinical 
FR180204 (reversible-ATP 
competitive)/ FR148083 (covalent) 
ERK1/2 Astellas pharmaceuticals Pre-clinical 
GDC-0994 ERK1/2 Genentech/Array BioPharma Phase I 
CC-90003 ERK1/2 Celgene Phase I 
AZ13767370 ERK1/2 AstraZeneca Pre-clinical 
KO-947 ERK1/2 Kura Oncology Phase I 
LY3214996 ERK1/2 Eli Lilly Phase I 
CC-90003 ERK1/2 Celgene Phase I 
Ravoxertinib (GDC-0994, RG-7842) ERK1/2 Genentech Phase I 
MK-8353, SCH900353 ERK1/2 Merck Sharp & Dohme Phase I 
BVD-523, Ulixertinib ERK1/2 BioMed Valley Discoveries Phase I/II 
Table 1.3: ERK clinical inhibitors. Adapted from (Kidger et al., 2018; Ryan et al., 2015) 
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than MEK inhibitors due to the ability to block phosphorylation of ERK as well as inhibit 
the catalytic activity. Some of the current ERK inhibitors being evaluated in the clinic are 
listed in Table 1.3. 
PI3K 
The PI3Ks are heterodimeric lipid kinases that have catalytic and regulatory/adaptor 
subunits encoded by several genes and alternative splicing. The PI3Ks play several roles 
in the cell, from cellular growth, transformation and adhesion to survival and motility, 
which makes it an important player in cancer (Castellano and Downward, 2011). 
Additionally, the role of PI3K in the inhibition of apoptosis and promotion of 
tumorigenesis has been reported, cementing its role in cancer (She et al., 2005; Will et al., 
2014). The PI3K family can be divided into three main classes of enzymes (class I, II and 
III), based on substrate specificity, regulation and structure. The catalytic subunits for class 
I PI3Ks, the most well characterized class, are p110α, p110β, p110γ and p110δ. These are 
the products of the PIK3CA, PIK3CB, PIK3CG and PIK3CD genes, respectively 
(Castellano and Downward, 2011; Vivanco and Sawyers, 2002). p110 subunits are often 
divided into class IA groups which bind the p85 subunit (α, β and δ), and class IB, which 
do not.  
Activation of PI3K can occur through three independent pathways that are initiated by 
ligand binding to RTKs, which causes dimerization, auto phosphorylation and activation 
(Pawson and Nash, 2003; Schlessinger, 2002). The first occurs upon the SH2 domain of 
p85 binding to phospho-YXXM motifs in the RTKs, which triggers p110 catalytic 
activation (Figure 1.4) (Domchek et al., 1992). Activation can also occur through the 
adaptor protein GRB2, which can bind phospho-YXN motifs in the RTK (Pawson, 2004). 
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GRB2 can bind to the scaffolding protein GAB, which activates p85. The third pathway to 
initiate PI3K signaling occurs through activation of RAS, which occurs through GRB2 
binding SOS which leads to activation of RAS. RAS can then directly activate the p110 
subunit of PI3K independently of p85 (Castellano and Downward, 2011). PI3K has been a 
target of numerous drug discovery efforts, listed in Table 1.4. 
PI3K inhibitor Target Company Clinical Phase 
Buparlisib (BKM120) Pan-PI3K Novartis III 
Pictilisib (GDC-0941) Pan-PI3K Genentech II 
Sonolisib (PX-866) Pan-PI3K Oncothyreon II 
Pilaralisib Pan-PI3K Sanofi Oncology/Exelixis II 
Copanlisib Pan-PI3K Bayer FDA approved 
Dactolisib (BEZ235) PI3K/MTOR Novartis Discontinued 
Omipalisib (GSK2126458) PI3K/MTOR GlaxoSmithKline I 
Gedatolisib PI3K/MTOR Wyeth/Pfizer III 
Apitolisib (GDC-0980) PI3K/MTOR Genentech I 
Bimiralisib (PQR309) PI3K/MTOR PIQUR Therapeutics I/II 
Alpelisib p110α Novartis III 
Taselisib p110β-sparing Roche (Genentech) III 
GSK2636771 p110β GlaxoSmithKline I/II 
AZD8186 p110β AstraZeneca I 
SAR260301 p110β Sanofi I 
Nivolumab (IPI-549) p110γ Infinity Pharmaceuticals I 
Table 1.4: PI3K clinical candidates. Adapted from (Janku, 2017), with additional information from the NCI 
and ASCO websites. 
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Prevalence of Aberrant KRAS Signaling in GI Cancers 
Colorectal Cancer 
Colorectal cancer (CRC) is the second leading cause of cancer related deaths worldwide 
(Jemal et al., 2011). According to the 2017 American Cancer Society statistics, early stage 
disease (Stage I – III) 5-year survival rates exceed 70% on average, while patients with 
distant (metastatic) disease have 5-year survival rates of ~13-14% (Siegel et al., 2017). It 
is recognized that metastatic colorectal cancer (mCRC) has a dismal prognosis and lacks 
effective therapies. Presently, mCRC patients are treated with a combination of 
fluoropyrimidine (5-fluorouracil or 5-FU) or capecitabine with either oxaliplatin 
(FOLFOX) or irinotecan (FOLFIRI) (Prenen et al., 2010). However, two monoclonal 
antibodies targeting epidermal growth factor receptor (EGFR) have been approved for 
treatment of mCRC:  panitumumab and cetuximab. Cetuximab competitively inhibits 
ligand binding and has shown clinical activity as a single agent and in combination with 
irinotecan for the treatment of mCRC (Cunningham et al., 2004; Jonker et al., 2007; Saltz 
et al., 2004; Sobrero et al., 2008). Despite the high incidence rate of KRAS mutations in 
colorectal cancer, a consensus on the prognostic effect of KRAS mutations does not exist 
based on numerous studies of all stages of CRC. However, it has been shown that patients 
harboring a KRAS or BRAF mutation are not responsive to EGFR-based therapies (Lievre 
et al., 2006). KRAS mutations have therefore become a biomarker that preclude patients 
from EGFR based therapies, creating a critical unmet need for this metastatic CRC patient 
population. 40-50% of patients diagnosed with CRC have a mutation in KRAS, which 
makes these patients viable candidates for therapies targeting RAS signaling (covered in 
Chapter 3). 
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Pancreatic Cancer 
Pancreatic cancer is currently the third leading cause of cancer-related deaths in the United 
States and has the lowest 5-year relative survival rate of any cancer (Rahib et al., 2014; Siegel 
et al., 2016). Projections predict it will surpass breast and colorectal cancer by 2030 to become 
the second leading cause of cancer-related deaths (Rahib et al., 2014). General advancements 
in screening, prevention and treatment of cancer has positively impacted cancer incidence and 
mortality rate for most cancers, while pancreatic cancer has lagged in this area. This disease is 
recalcitrant to chemotherapeutic approaches as first-line therapy and recently approved 
therapies afford only modest improvements in survival. Few targeted therapies exist for the 
treatment of pancreatic cancer and because of poor outcome with standard therapies, patients 
are often encouraged to participate in clinical trials. Consequently, the 5-year survival rate 
since the 1970’s has only improved from 3% to 8%, and patients diagnosed with metastatic 
pancreatic cancer have a life expectancy of 2.8-5.7 months (Carrato et al., 2015; Siegel et al., 
2016). There exists a critical unmet need for development of novel treatments for patients 
diagnosed with this disease.  
The most commonly mutated genes in pancreatic cancer are KRAS, which occurs in over 90% 
of tumors, and CDKN2A (>90% of cases), the gene encoding for endogenous CDK4/6 
inhibitor p16ink4a (Jaffee et al., 2002; Liggett and Sidransky, 1998; Maitra and Hruban, 2008). 
p16 is a potent suppressor of oncogenic transformation and a key mediator of Ras induced 
senescence, a tumor suppressor phenomenon that occurs upon oncogenic transformation of 
fibroblasts with the Ras oncogene that causes them to senesce (Serrano et al., 1997). CDK4/6 
is a kinase critical for progression of the cell cycle and is widely considered to be the gatekeeper 
of the restriction point in the G1 to S transition phase (Blagosklonny and Pardee, 2002). A 
therapeutic approach dual-targeting MEK and CDK4/6 is covered in Chapter 2. 
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Dissertation Objectives 
The goal of this dissertation is to delineate novel strategies for the treatment of patients 
diagnosed with RAS activated pancreatic or colorectal cancer. Novel strategies explored 
here include dual-targeting of MEK and CDK4/6 as well as the rational design and 
evaluation of a novel dual-inhibitor of EGFR and PI3K (MTX-211). The following 
individual chapters describe two very different approaches to develop improved therapies 
for the treatment of pancreatic and colorectal cancer, one involving the use of pre-existing 
agents and the other involving the design of new agents. 
Chapter 2: Co-targeting MEK and CDK4/6 in pancreatic cancer and discovery of 
predictive biomarkers of activity. 
Chapter 3: Design and evaluation of the novel, first-in-class small molecule dual 
EGFR/PI3K inhibitor MTX-211 for its potential utility in combination with MEK 
inhibition in colorectal cancer. 
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Appendix A 
 
Information presented and reviewed in Chapter 1 was published in Cancer Discovery. 
Maust, J.D., Whitehead C.E., Sebolt-Leopold, J.S. (2018) Oncogenic Mutants of 
MEK1: A Trilogy Unfolds. Cancer Discovery. doi:10.1158/2159-8290.CD-18-
0192 
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Chapter 2: Co-Targeting MEK and CDK4/6 to Treat KRAS 
Mutant Cancer 
 
Summary 
The ineffectiveness of chemotherapy in patients with pancreatic cancer highlights a critical 
unmet need in pancreatic cancer therapy. Two commonly mutated genes in pancreatic 
cancer, KRAS and CDKN2A, have an incidence exceeding 90%, supporting investigation 
of dual targeting of MEK and CDK4/6 as a potential therapeutic strategy for this patient 
population. An in vitro proliferation synergy screen was conducted to evaluate response of 
a panel of high passage and patient-derived pancreatic cancer models to the combination 
of trametinib and palbociclib to inhibit MEK and CDK4/6, respectively. Two 
adenosquamous carcinoma models, L3.6pl and UM59, stood out for their high synergy 
response.  In vivo studies confirmed that this combination treatment approach was highly 
effective in subcutaneously implanted L3.6pl and UM59 tumor-bearing animals. Both 
models were refractory to single agent treatment.  Reverse phase protein array analysis of 
L3.6pl tumors excised from treated animals revealed strong down regulation of 
cyclooxygenase-2 (COX-2) expression in response to combination treatment. Expression 
of COX-2 under a CMV-driven promoter and shRNA knockdown of COX-2 both led to 
resistance to combination treatment. Our findings suggest that COX-2 may be involved in 
the improved therapeutic outcome seen in some pancreatic tumors that fail to respond to 
MEK or CDK4/6 inhibitors alone but respond favorably to their combination. 
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Introduction 
Pancreatic cancer is the third leading cause of cancer-related deaths in the US and has the 
lowest 5-year relative survival rate of any cancer (Rahib et al., 2014; Siegel et al., 2016). 
This disease is recalcitrant to chemotherapeutic approaches and recently approved 
therapies afford only modest improvements in survival.  Consequently, the 5-year survival 
rate since the 1970’s has only improved from 3% to 8% (Siegel et al., 2016). There exists 
a critical unmet need for development of novel treatments for patients diagnosed with this 
disease.  
The most commonly mutated genes in pancreatic cancer are KRAS, which occurs in over 
90% of tumors, and CDKN2A (inactivated in >90% of cases), the gene encoding the 
endogenous CDK4/6 inhibitor p16INK4a (Cox et al., 2014; Jaffee et al., 2002; Liggett and 
Sidransky, 1998; Maitra and Hruban, 2008). KRAS is a small GTPase that activates the 
mitogen activated protein kinase (MAPK) signaling pathway, whereas p16 is a potent 
suppressor of oncogenic transformation and a key mediator of RAS induced senescence 
(Serrano et al., 1997). While MEK inhibitors have exhibited potent in vitro activity in 
KRAS mutant tumor cells (Wee et al., 2009), the in vivo activity of these agents has been 
disappointing due to the development of resistance (Little et al., 2011; Poulikakos and 
Solit, 2011; Turke et al., 2012b; Wee et al., 2009).  
An attractive target for MEK inhibitor-based combinations is CDK4/6, a kinase crucial for 
the transition from G1 to S phase (Blagosklonny and Pardee, 2002). In support of co-
targeting MEK and CDK4/6, a synthetic lethal interaction between KRAS and CDK4 was 
found in non-small cell lung cancer (Puyol et al.).  Furthermore, CDK4 was identified as a 
key driver of an alternative phenotype induced by MEK inhibition, but not genetic 
 29 
 
extinction of NRAS in mouse models of melanoma (Kwong et al., 2012). Our laboratory 
as well as Kopetz and colleagues subsequently demonstrated in vivo efficacy of this 
combination approach in KRAS mutant patient-derived xenograft (PDX) models of 
colorectal cancer (Lee et al., 2016; Ziemke et al., 2015). Pancreatic cancers should also 
derive therapeutic benefit from this combination strategy based on their genomic features. 
Specifically, activating KRAS mutations have been shown to initiate formation of 
premalignant lesions in mouse models of pancreatic cancer, while loss of p16 has been 
shown to enable their malignant progression (Bardeesy et al., 2006). Ectopic p16 
expression can induce senescence and apoptosis when reintroduced into pancreatic cancer 
cell lines with CDKN2A deletions (Calbo et al., 2001). Since CDK4 and CDK6 are the 
sole targets of p16, a unique opportunity is present to leverage recently approved CDK4/6 
inhibitors to recapitulate this phenotype in pancreatic cancer.  
The effectiveness of dual targeting of MEK and CDK4/6 to treat pancreatic cancer has 
been reported for high passage models (Franco et al., 2016; Franco et al., 2014). The 
present report extends these findings to include patient derived xenograft (PDX) models of 
pancreatic cancer and concurrent phosphoproteomic profiling to identify potential 
prognostic biomarkers of response. We report here that two adenosquamous pancreatic 
models are highly responsive to dual targeting of these kinases both in vitro and in vivo.  
We further find that genetic manipulation of cyclooxygenase-2 (COX-2) expression, which 
is highly expressed in both of these models, blunts therapeutic effectiveness of combination 
treatment.  Our results therefore provide the impetus to further explore the prognostic role 
of COX-2 to aid in the identification of a subpopulation of pancreatic cancer patients who 
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might derive the greatest therapeutic benefit from combination therapy directed against 
MEK and CDK4/6. 
Materials and Methods 
Chemicals 
Trametinib and binimetinib (MEK162) were purchased from LC Laboratories. Ribociclib 
(LEE011) was purchased from Chemietek. Palbociclib isethionate was purchased from 
Selleckchem. Drug stocks were dissolved in DMSO at 10 mM and stored at -20 °C. 
Cell proliferation assays 
For growth inhibition and synergy analyses, cells were seeded in white-walled/clear bottom 
tissue culture treated 96-well plates at 5,000-10,000 cells/well and allowed to adhere for 
24 hours followed by addition of growth media containing serial dilutions of trametinib, 
palbociclib, or both drugs in combination. Cells were incubated for 5 days in the continuous 
presence of drug or DMSO and viability was measured using CellTiter-Glo (Promega). 
Viability was calculated as a percentage of DMSO treated cells.  Concentration response 
curves were modeled using a nonlinear regression curve fit with a sigmoidal concentration 
response using GraphPad Prism 6.  Synergy plot calculations were performed using 
Combenefit software (Cancer Research UK Cambridge Institute) and scores were 
generated using Chalice Bioinformatics Software (Horizon Discovery Group), both using 
the Loewe model of synergy. 
Cell lines 
All cell lines were cultured at 37°C in 5% CO2 in 10% FBS and 1% penicillin/streptomycin 
(Thermo Fisher Scientific). L3.6pl, pL45, MiaPaCa-2, Panc-1 and HS766T cell lines were 
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grown in DMEM. HPAFII was grown in EMEM. ASPC1, Bxpc-3 and Panc10.05 were 
cultured in RPMI media. The PDX models UM8, UM15, UM16, UM19, UM32, UM53, 
UM59, UM81, UM90, UM91 and UM123 originated from patients undergoing surgical 
resection at University of Michigan and were established to grow in animals and in culture.  
All PDX lines were grown in RPMI media. All lines were negative for mycoplasma 
contamination when tested with MycoAlert Mycoplasma Detection Kit (Lonza). All high 
passage cell lines were authenticated by short tandem repeat (STR) profiling at the 
University of Michigan Sequencing Core. 
Cell cycle analysis 
Cells were seeded into 6 well plates at ~150,000 cells/well and treated the next day at the 
indicated concentrations, with a maximum DMSO concentration of 0.1%. Cells were 
harvested with 0.05% trypsin, washed twice with PBS and fixed with 70% ethanol at 4°C 
for at least 24 hr. Cells were washed twice with PBS and incubated for 30 minutes in a 
solution of 50 μg/ml propidium iodide (Life Technologies, P3566), 0.1% Triton X- 100 
(Sigma-Aldrich, T9284), 50 μg/ml RNase A (Qiagen, 1007885) and PBS. Data were 
collected on a Cyan ADP Analyzer (Beckman Coulter), with collection of at least 10,000 
events. The analysis was performed using flow cytometry analysis software ModFit LT 
V4.0.5 (Verity Software House). 
Animal studies 
Cells (1 x 106) were injected subcutaneously into the region of the right axilla of 6- to 7-
week-old female NCR nude mice (NCRNU-F sp/sp CrTac:NCr-Foxn1nu, Taconic) in a 
50:50 mixture of DMEM/F12 and Matrigel. Tumors were allowed to grow until 150-300 
mm3, at which time mice were randomized into different treatment groups (4-5 animals per 
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group). Trametinib and palbociclib were administered as a fine suspension in 0.5% 
hydroxypropyl methylcellulose (HPMC) with 0.2% Tween-80 or saline, respectively, 
based on individual animal body weight (0.2 ml/20 g), once daily via oral gavage. Tumor 
volumes were measured using calipers and calculated using the formula: tumor volume = 
(length*width2)/2. Efficacy was calculated as the ratio of change in mean tumor burdens at 
time t (∆T/∆C) where ∆T and ∆C is calculated as mean tumor burden at time t minus the 
mean tumor burden on the first day of treatment. Percent regression is calculated as [– 
(∆T/T0)*100], where T0 is initial body weight of treated animals. Tumor growth delay was 
calculated based on the time required for the mean to reach ~750 mm3. Where applicable, 
statistical significance between groups was calculated on the last day of treatment via one-
way ANOVA analysis with multiple comparisons between all treatment arms. 
Western blotting and reverse-phase protein array (RPPA) analysis 
Cells were harvested by scraping in the presence of radioimmunoprecipitation (RIPA) 
buffer plus phosphatase and protease inhibitors (Roche). Samples were denatured and 
normalized to 1 μg/μl in LDS sample buffer (ThermoFisher) and 62.5 mM DTT 
(ThermoFisher). For immunoblotting, multiple independent immunoblots were used to 
present data from single experiments. Loading controls were probed on the same blot, with 
a representative image shown for experiments with multiple antibodies. Ten micrograms 
of protein were run on precast 4-12% polyacrylamide gels (ThermoFisher). The following 
antibodies were used: pRb S780, pRb S807/11, Cdc6, total Rb, pERK, cyclin D1, COX-2, 
EGFR Y1068, FOXM1 (Cell Signaling), Pdcd4 (Rockland), Beta-actin and GAPDH 
(Abcam). For RPPA analysis, tumors were homogenized and protein was extracted 
utilizing NP-40 lysis buffer plus phosphatase and protease inhibitors. Samples were 
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denatured and normalized to 1 μg/μl in SDS sample buffer/β-mercaptoethanol 
(ThermoFisher) and shipped to the MD Anderson RPPA Core Facility, where samples were 
profiled and processed. Per the protein loading protocol, all antibodies were median 
centered per antibody, then median centered per sample, and log2 normalized. Trametinib, 
palbociclib and combination treated samples were compared to control samples using a 
two-sample t-test for each treatment/control comparison. T-test p-values were adjusted for 
multiple testing using the FDR method and resulting qValues < 0.1 were considered to 
represent significant changes. Significant antibodies and treatment sample replicates are 
clustered using agglomerative hierarchical clustering with a Euclidean distance metric. 
Immunohistochemistry 
Tissues were fixed in 10% NBF, embedded in paraffin and sectioned according to standard 
procedures. The Ki67 antibody was obtained from Cell Signaling Technology. 
Representative images were obtained with a Nikon E-800 microscope, Olympus DP71 
digital camera, and DP Controller software. To quantify the ratio of Ki67 positive nuclei 
to total nuclei, 5-8 snapshots of different sections of the tumor were used to determine the 
average Ki67 nuclear ratio using online software tool ImmunoRatio (Tuominen et al., 
2010). Statistical significance was calculated between groups using one-way ANOVA 
(GraphPad Prism). 
COX-2 plasmid construction and shRNA transduction 
Full length human COX-2 cDNA was excised as a BamHI/XhoI fragment from the 
huCOX-2 pcDNA5/FRT/TO construct, generously provided by Dr. William Smith 
(University of Michigan, Ann Arbor, MI), and ligated into pcDNA3.1. Transfections of 
L3.6pl cells were performed in six-well dishes using huCOX-2 pcDNA3.1 linearized with 
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Bgl II (2.5 µg plasmid/well) and Lipofectamine 2000 (ThermoFisher) according to 
manufacturer’s instructions.  Clones stably expressing full length human COX-2 were 
established after selection in medium containing 1 mg/mL G418 (ThermoFisher). Control 
(sc-108080) and COX-2 (sc-29279-V) shRNA lentiviral particles (Santa Cruz 
Biotechnology) were transduced into cells according to manufacturer’s directions and 
clones were established after selection with 10 µg/ml puromycin. 
Reverse-transcription quantitative PCR (RT-qPCR) 
Total RNA was isolated from cell lines treated for 5 days using the RNeasy Mini Kit 
(Qiagen).  First-strand cDNA was reverse-transcribed from total RNA using the 
SuperScript III First-Strand Synthesis System (Invitrogen) according to the manufacturer’s 
instructions.  Quantitative targeted amplification of cDNAs was performed using Taqman 
Gene Expression Assays primer/probe sets for COX-2 (Hs00153133_m1), Pdcd4 
(Hs00377253_m1), GAPDH (Hs02786624_g1) and Fast Advanced Master Mix (Thermo 
Fisher) according to the manufacturer’s instructions. GAPDH was used as an endogenous 
control. The amplification conditions for the ViiA 7 Real-Time PCR System (Applied 
Biosystems) consisted of an initial step of 2 min at 50°C and 10 min at 95°C followed by 
40 cycles of 15 sec 95°C, 1 min 60°C.  For treated cells, data were analyzed using the ΔΔCt 
method and expressed as fold change over control. Data from the panel of cell lines were 
calculated as one Ct equals a 2-fold difference in expression and are represented as relative 
expression to the highest expressing cell line.  
 35 
 
Results 
Inhibitors of MEK and CDK4/6 synergistically inhibit pancreatic cancer cell line 
growth 
Screening of high passage and PDX models of pancreatic cancer was carried out to identify 
models in which the combined action of trametinib and palbociclib showed the greatest 
degree of synergy. Cell lines showed a wide range of response to combination treatment, 
as depicted in Figure 2.1A where models are listed in the order of a consolidated synergy 
score. L3.6pl cells showed the highest degree of synergy followed by UM59 cells, with 
both models exhibiting at least a two-fold increase over the panel median (2.35) (Fig. 
2.1B).  Synergistic response was greatest in response to the combination of trametinib and 
palbociclib at concentrations of 10 nM and 1 µM, respectively, concentrations which led 
to a median reduction in viability of 59% across the panel (Supplementary Fig. 2.7/S1A).  
These optimal concentrations are consistent with our previous work in colorectal cancer 
models (Ziemke et al., 2015) as well as the studies of others carried out in lung cancer 
models (Tao et al., 2016).  A similar degree of synergy was observed when L3.6pl cells 
were treated with the MEK inhibitor binimetinib (Cheng and Tian, 2017) and the CDK4/6 
inhibitor ribociclib (Duso et al., 2018), confirming that synergy is not likely attributable to 
off target activities (Supplementary Fig. 2.7/S1B).  Comparative analysis of concentration 
response curves for high (L3.6pl), intermediate (UM59) and low (Bxpc-3 and Panc10.05) 
synergy models is shown in Figure 2.1C to better understand the relationship between 
synergy and sensitivity.  As shown here, the degree of synergy decreased as the 
concentration of trametinib was raised. No synergy was observed in Bxpc-3 and Panc10.05 
cells at concentrations greater than approximately 20 nM, where the concentration response 
curves for trametinib single agent and the combination treatment plots intersect. In contrast, 
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the concentration response curves for L3.6pl cells never intersected, since viability could 
not be reduced beyond 50% despite use of high (1-10 µM) concentrations of trametinib. 
These cells are also refractory to palbociclib treatment alone (Supplementary Figure 
2.8/S2A). 
Co-targeting MEK and CDK4/6 leads to profound G1 arrest 
MEK and CDK4/6 have both been shown to play a role in controlling cell cycle 
progression, either through induction of cyclins or phosphorylation of Retinoblastoma 
protein (Rb), a master regulator of G1-S progression. Cell cycle studies carried out in the 
L3.6pl and UM59 models confirmed that combination treatment with trametinib and 
palbociclib induces a strong time-dependent G1 arrest at concentrations previously shown 
to be synergistic (Fig. 2.2A). Immunoblotting analysis further revealed that expression 
levels of Cdc6, a protein critical for initiation of DNA synthesis and pre-replication 
complex assembly (Braden et al., 2008; Liu et al., 2000), and phosphorylated Rb, were 
selectively reduced in L3.6pl cells treated with the combination, consistent with G1 arrest 
(Fig. 2.2B). These data suggest that synergy between trametinib and palbociclib to inhibit 
cell growth is driven at least in part by enhancement of G1 arrest. 
Uncoupling of Cyclin D1 and pRB expression in response to MEK inhibition is cell 
line dependent      
Immunoblotting analyses confirmed that phosphorylated ERK levels were suppressed by 
trametinib treatment in all lines at concentrations consistent with a reduction in viability 
(Fig. 2.3A & 2.3B). MEK inhibition additionally led to a reduction of total and 
phosphorylated Rb levels in a concentration-dependent manner. This result is not 
surprising, as MAPK signaling has been shown to contribute to control of cyclin D1 
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expression in response to growth factor stimulation (Lavoie et al., 1996), thereby indirectly 
reducing CDK4/6 phosphorylation of Rb. Cyclin D1 levels were recalcitrant to MEK 
inhibition in cell lines previously found to be most responsive to combination treatment 
(L3.6pl, UM59), despite reduction in pRb expression. This reduction in pRb can be 
explained by increased p27 expression in response to trametinib treatment (Supplementary 
Fig. 2.8/S2B), which has been shown to bind and contribute to inhibition of the 
CDK4/cyclin D complex (Ray et al., 2009). In contrast, models showing a low degree of 
synergy (Panc10.05, Bxpc-3) exhibited significant reduction in levels of both cyclin D1 
and pRb in response to trametinib single agent treatment. While UM59 may be as sensitive 
to trametinib as Panc10.05 and Bxpc-3 (Fig. 2.3A), trametinib clearly shows cell line-
dependent effects on expression of these cell cycle proteins, likely contributing to 
comparative differences in synergistic potential with palbociclib. Collectively, these data 
suggest that tumors exhibiting MEK-dependent uncoupling of cyclin D1 and pRb 
expression in vitro may be most sensitive to dual targeting of MEK and CDK4/6. 
Combination treatment with trametinib and palbociclib provides therapeutic benefit in 
vivo 
Based on the high degree of in vitro synergy seen when MEK and CDK4/6 are both 
inhibited in L3.6pl cells, we evaluated the in vivo efficacy of the combination of trametinib 
and palbociclib in L3.6pl tumor-bearing animals. Daily treatment was initiated when 
tumors were advanced (~300 mm3) for a total of 7 days.  No signs of toxicity were noted 
at the doses administered. Neither single agent elicited a meaningful effect on ∆T/∆C or 
tumor growth delay after cessation of treatment (Fig. 2.4A).  In contrast, a ∆T/∆C of 28% 
and a tumor growth delay of 10 days was observed in the combination arm. Tumors were 
harvested on the last day of treatment for immunohistochemical analysis of Ki67 
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expression (Fig. 2.4B-C), revealing a significant reduction in expression in tumors from 
the combination group compared to the control and single agent groups.  The results from 
this study were subsequently confirmed with less advanced L3.6pl tumors at treatment 
initiation, showing a ∆T/∆C of 1% and a 15 day growth delay, versus 1 & 2 days for 
trametinib and palbociclib, respectively (Supplementary Fig. 2.9/S3).  
COX-2 expression is downregulated and Pdcd4 is upregulated in response to co-
targeting of MEK and CDK4/6 
L3.6pl tumors evaluated for in vivo efficacy were further analyzed for selective proteomic 
changes as a consequence of combination treatment.  Two proteins, COX-2 and 
programmed cell death 4 (Pdcd4), emerged from Reverse Phase Protein Array (RPPA) 
analyses showing inverse dysregulation in response to treatment with trametinib and 
palbociclib (Fig. 2.4D). COX-2 expression showed the highest magnitude of change in the 
combination arm among all the proteins measured in the RPPA platform. Palbociclib 
treatment caused a small decrease in COX-2, but this change was not significant. Others 
have noted the role of palbociclib in mediating a c-jun-dependent decrease in COX-2 
expression, but the impact of this change outside of the epithelial-mesenchymal transition 
is unclear (Qin et al., 2015).  An induction of Pdcd4 expression in response to the 
combination of trametinib and palbociclib was also observed, suggesting that dual targeting 
of MEK and CDK4/6 leads to initiation of cell death signaling. It appears that this effect is 
independent of apoptosis, as no significant changes were observed in PARP, caspase-3, 7 
or 8 in the RPPA dataset (Fig. 2.4D).  Subsequent immunoblotting studies were carried out 
to confirm that COX-2 is downregulated and Pdcd4 is upregulated in response to 
combination treatment with trametinib and palbociclib (Fig. 2.4E). Modulation of these 
biomarkers at the RNA level was addressed by carrying out RT-qPCR analysis of treated 
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L3.6pl and UM59 cells, showing a reduction of COX-2 and an increase in Pdcd4 in treated 
samples of both cell lines (Supplementary Fig. 2.10/S4A; UM59 protein expression 
changes shown in Fig. 2.10/S4B). Given that a decrease in COX-2 expression was the most 
significant change associated with activity in this study, we tested the COX-2 inhibitors 
celecoxib and NS-398 in the L3.6pl and UM59 models. Neither COX-2 inhibitor elicited 
significant anti-proliferative effects at concentrations lower than 50 μM.  Concentrations 
in this range have been associated with COX-independent effects and have not been 
achieved in humans (Supplementary Fig. 2.10/S4C) (Davies et al., 2000; Hawk et al., 
2002). The lack of efficacy is not surprising, as significant increases in COX-2 expression 
in response to these inhibitors has been shown (Ferguson et al., 1999). 
Ectopic overexpression of COX-2 lowers sensitivity to dual inhibition of MEK and 
CDK4/6 
Based on the reduction of COX-2 expression seen when cells were co-treated with 
trametinib and palbociclib, experiments were undertaken to explore a direct role for COX-
2 in affecting sensitivity to dual inhibition of MEK and CDK4/6. FOXM1, a transcription 
factor whose stability is controlled by CDK4/6 phosphorylation (Anders et al., 2011) and 
whose activity and cellular localization is controlled by ERK (Ma et al., 2005b), could be 
involved in driving this reduction in COX-2. This is possible considering FOXM1 activity 
has been implicated in promoting transcription of COX-2 in conjunction with Sp1 (Xu and 
Shu, 2013a). The expression of FOXM1 is decreased selectively in L3.6pl cells exposed to 
combination treatment (Fig. 2.5A). Therefore, we hypothesized that combination treatment 
leads to synergy by decreasing expression of COX-2 through abrogation of FOXM1 
activity. To test this hypothesis, a COX-2 plasmid under control of the cytomegalovirus 
(CMV) promoter was constructed for ectopic expression in L3.6pl cells.  In this manner, 
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removal of endogenous control of COX-2 expression would render cells unresponsive to 
FOXM1. After transfection, clones were selected and lysates were generated to track COX-
2 expression, whereupon clone L3.6pl-C5 was found to comparatively exhibit the highest 
amount of COX-2 (Fig. 2.5B). Synergy of the parent line to the combination of trametinib 
and palbociclib was subsequently compared to that of the L3.6pl-C5 line and found to be 
significantly higher (synergy score, 7.35 vs 1.69, respectively). This finding suggests that 
overexpression of COX-2 by removing it from endogenous control influences the degree 
of synergy observed between trametinib and palbociclib. Importantly, response of the 
L3.6pl-C5 line to single agent treatment remained unchanged in comparison to the parent 
line (Supplementary Fig. 2.11/S5A). However, the L3.6pl-C5 line showed a blunted shift 
in the concentration response curves when combining both agents at clinically relevant 
concentrations (1 to 10 nM trametinib and 100 nM to 1 μM palbociclib) (Supplementary 
Fig. 2.11/S5B). This provides evidence that, although changes in COX-2 expression may 
not significantly affect response to either single agent, therapeutic efficacy of the 
combination is reduced upon alternate transcriptional control of COX-2. 
To confirm these findings in vivo, the parent and C5 lines were compared in tumor-bearing 
animals in a head to head study comparing efficacy from single agent vs combination 
therapy (Fig. 2.5C). On the last day of treatment, combination treated animals implanted 
with the parent line exhibited a ∆T/∆C value of 17%, confirming the in vitro synergy seen 
with this combination against the L3.6pl model.  In contrast, animals implanted with COX-
2 overexpressing C5 tumors, exhibited a ∆T/∆C value of 57%. Lysates generated from 
tumors harvested on the last day of treatment showed decreased FOXM1 expression in 
both studies, consistent with earlier in vitro studies. Furthermore, a greater ability of 
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combination treatment to decrease COX-2 expression was observed in the parent line in 
comparison to L3.6pl-C5 (Supplementary Fig. 2.11/S5C). These results suggest that 
endogenous COX-2 expression in a model with high COX-2 expression is critical for 
activity and removing this factor substantially reduces in vivo efficacy of combination 
therapy in the L3.6pl model. 
Knockdown of COX-2 reduces synergy to MEK and CDK4/6 
Studies were designed to test the hypothesis that reduction of COX-2 expression through 
transcriptional control affects response to combination treatment. To explore the impact of 
COX-2 knockdown, L3.6pl and UM59 cells were virally transduced with COX-2 and 
control shRNA vectors. Despite harvesting numerous clones (>30), COX-2 was not 
successfully knocked down in UM59 cells, presumably due to reliance on expression for 
survival. In L3.6pl cells, transduction resulted in a successful knockdown of COX-2 (Fig. 
2.5D). When these cells were evaluated for their response to combination treatment, 
knockdown cells showed reduced synergy in comparison to control cells (Fig. 2.5E). This 
reduction in synergy is consistent with results obtained with cells previously transfected 
with CMV-controlled COX-2 (Fig. 2.5F), confirming the impact of COX-2 expression 
levels on therapeutic outcome in this model. 
Low innate expression of COX-2 correlates with reduced benefit to combination 
treatment 
In L3.6pl tumors, COX-2 appears to play a role in potentiating response to combination 
treatment.  We explored the potential of COX-2 to serve as a prognostic marker of response 
to combination treatment across a broad panel of pancreatic cancer models. Lysates 
prepared from our pancreatic cell line panel were probed for expression of COX-2 (Fig. 
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2.6A). COX-2 appears as several bands, which likely represent different potential post-
translational modifications, since this protein has multiple sites for potential N-linked 
glycosylation, phosphorylation, and myristoylation (Wennogle et al., 1995). The 
expression levels of COX-2 in these lines was confirmed via RT-qPCR of RNA harvested 
from the panel (Supplementary Fig. 2.12/S6A).  L3.6pl and UM59 showed relatively high 
expression of COX-2 alongside Bxpc-3. Whereas L3.6pl and UM59 both exhibited a high 
degree of in vitro synergy to the combination of trametinib and palbociclib, a low synergy 
score was observed for the Bxpc-3 model.  The lack of in vitro synergy seen here for Bxpc-
3 cells is consistent with the observation that this model is exquisitely sensitive to MEK 
inhibition alone both in vitro and in vivo (Allen et al., 2003). Like L3.6pl, the UM59 model, 
which exhibited the second highest in vitro synergy score, showed improved therapeutic 
response when exposed to combination treatment, as evidenced by a 16-day tumor growth 
delay and ∆T/∆C of 5% compared to ineffective single agent therapies (Fig. 2.6B). Neither 
L3.6pl nor UM59 tumors were responsive to MEK inhibition alone.  Panc-1 and Panc10.05 
tumors, which exhibit low COX-2 expression (Supplementary Fig. 2.12/S6B) and low in 
vitro synergy scores, showed somewhat improved response in the combination arms, as 
reflected by a ∆T/∆C value of 14% and percent regression of 21%, respectively.  Most 
notably, one tumor-bearing mouse for each of these models showed a complete regression 
when treated with the combination. However, the overall improvement in response of these 
models to combination treatment compared to either single agent, as measured by tumor 
growth delay or ∆T/∆C, was reduced compared to the L3.6pl and UM59 models, which are 
characterized by high COX-2 expression. Therefore, consistent with our in vitro data, 
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tumors exhibiting low COX-2 expression do not appear to derive as much added benefit 
from the combination regimen. 
Discussion 
Novel therapeutic approaches for the treatment of pancreatic cancer are urgently needed 
due to the lack of significant improvements in patient survival over the past 40 years. 
Recent clinical approval of the CDK4/6 inhibitor palbociclib provides potential new 
opportunities for the treatment of cancers harboring CDKN2A (p16ink4a) aberrations, 
which includes the majority of pancreatic cancers. Due to the high incidence of KRAS 
mutations in pancreatic cancer and their co-occurrence with CDKN2A inactivation, a 
combination therapy approach targeting MEK and CDK4/6 was evaluated here. Cell line 
synergy screening was carried out in both high passage and PDX models, whereupon two 
lines, L3.6pl and UM59, exhibited at least a twofold greater response over the median. 
Both models, when implanted in vivo, proved to be refractory to single agent treatment, 
while deriving substantial therapeutic benefit from the combination approach.  
Importantly, co-targeting MEK and CDK4/6 was further found to potentiate cell cycle 
arrest in both L3.6pl and UM59 cells over that with single agent CDK4/6 inhibition.  The 
prominent G1 arrest observed in our studies was confirmed by synergistic reductions in 
total levels of Cdc6, a protein critical for initiation of DNA synthesis and implicated in 
response to CDK4/6 modulation and RB output (Braden et al., 2008). Furthermore, 
reduction was seen in the expression of FOXM1, a transcription factor involved in cell 
cycle progression. It is a target of both ERK (Ma et al., 2005b) and CDK4/6 (Anders et al., 
2011), regulating cellular localization and stability, respectively.  
 44 
 
Concurrent phosphoproteomic profiling of treated L3.6pl tumors revealed the interesting 
finding that COX-2 expression was downregulated in response to dual inhibition of MEK 
and CDK4/6.  COX-2 is known for its role in mediating inflammation and promoting 
tumorigenesis in colorectal cancer and pancreatic cancer (Eberhart et al., 1994; Hill et al., 
2012; Ogino et al., 2008; Yip-Schneider et al., 2000). While COX-2 expression can be 
affected by inhibition of MAPK signaling (Elder et al., 2002; Huang et al., 2013; Schmidt 
et al., 2003), it is unclear how inhibition of CDK4/6 synergizes with MEK to decrease 
expression of COX-2 in the absence of an effect by MEK inhibition. The significant 
reduction that we see in expression of COX-2 upon dual inhibition of MEK and CDK4/6 
may ensue from reduced levels of FOXM1, as others have reported that COX-2 is in part 
controlled by FOXM1 activity (Ahmed et al., 2015; Xu and Shu, 2013a; Xu and Shu, 
2013b). Another protein whose expression was significantly altered by combination 
treatment in L3.6pl tumors was programmed cell death 4 (Pdcd4), which showed 
significant upregulation.  Studies have shown that this novel tumor suppressor negatively 
regulates gene expression by inhibiting Sp1/Sp3 binding at important motifs (Leupold et 
al., 2007) and may play a role in inactivating PI3K/AKT signaling and suppressing CCND1 
and CDK4 expression in NCSLC (Zhen et al., 2016). This finding has potential 
implications for the current study in which FOXM1 is reduced by combination treatment, 
as other groups have shown FOXM1 cooperating with Sp1 to promote COX-2 expression 
(Xu and Shu, 2013a). Pdcd4 may be regulated itself by direct phosphorylation through 
AKT (Palamarchuk et al., 2005). It is intriguing that studies have identified Pdcd4 to be in 
part responsible for the anticancer effects of COX-2 inhibitor NS-398 (Zhang and DuBois, 
2001) in colon carcinoma. Further studies are warranted to elucidate signaling dynamics 
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of these findings and further studies are ongoing to determine possible links. However, our 
studies unequivocally demonstrate that combining trametinib and palbociclib elicits a 
significant reduction of Ki67 staining in L3.6pl tumors, accompanied by a strong reduction 
in COX-2 and an increase in Pdcd4, both in vivo and in vitro. 
COX-2 was expressed under CMV promoter control to test the hypothesis that 
transcriptional control of COX-2 was responsible for the reduction in expression seen. 
Ectopic expression of COX-2 increased resistance to combination therapy efficacy and 
blunted the reduction of COX-2 seen in response to combination treatment. However, a 
modest but significant reduction was still seen in L3.6pl-C5 cells. This could be explained 
by a low level of endogenous COX-2 that continues to be expressed in these cells. Post-
translational degradation mechanisms may also be in place that are being induced by 
combination treatment. Reports indicate caveolin-1 co-localizes with COX-2 at the plasma 
membrane (Liou et al., 2001; Perrone et al., 2007) and participates in direct degradation of 
COX-2 (Chen et al., 2010). As a result, studies are warranted to investigate the role of 
caveolin-1 in the degradation of COX-2 in cells treated with combination therapy, as a 
modest increase in caveolin-1 expression was observed in the RPPA dataset in the 
combination arm. Furthermore, knockdown of COX-2 in L3.6pl cells blunted the 
synergistic response in comparison to control cells, confirming a role for COX-2 in 
mediating response to co-inhibition of MEK and CDK4/6. In summary, removing COX-2 
gene expression from endogenous control, either through knockdown or expression of 
CMV-promoter driven COX-2, reduces synergistic response. This is expected, as 
modulation of COX-2 expression via control of FOXM1 is ostensibly what leads to synergy 
when co-inhibiting MEK and CDK4/6. It is important to keep in mind that several models 
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in our study are exceptionally sensitive to either trametinib or palbociclib alone when tested 
in vitro.  Our data suggest that the usefulness of a synergy-based in vitro screen is biased 
towards models which show poor single agent activity. In particular, the L3.6pl model 
scored the highest in the in vitro combination screen and was subsequently shown to elicit 
no benefit from either single agent in vivo, while responding favorably to the combination.  
This is not to say that tumors exemplified by Panc-1 and Panc10.05, which produced low 
in vitro synergy scores, would not benefit from the combination in vivo.  In fact, both of 
these models showed one complete regression in the combination arm.  Their low synergy 
scores in vitro were partly due to their high in vitro sensitivity to trametinib alone. 
Nonetheless, trametinib monotherapy proved to be inactive in mice in all of the models 
tested here.  This highlights the disconnect between the in vitro and in vivo settings where 
tumor heterogeneity, tumor microenvironment and adaptive signaling play a role.  
Our goal was to identify models in which combination treatment disrupts signaling 
pathways that dictate their response. In vitro synergy screening facilitated the identification 
of two models, L3.6pl and UM59, that can derive substantial therapeutic benefit from dual 
targeting of MEK and CDK4/6.  In those models, the interesting observation was made that 
COX-2 expression levels influence therapeutic outcome. Endogenous COX-2 expression 
appears to be critical for activity and its ablation substantially reduces in vivo efficacy of 
combination therapy. Interestingly, both models are adenosquamous carcinomas of the 
pancreas, a highly aggressive form of pancreatic cancer reported to show strong expression 
of COX-2 (Brody et al., 2009; Katz et al., 2011; Meitner et al., 1983; Okami et al., 1999; 
Wang et al., 2012). Further studies are warranted to better understand the prognostic 
significance of high expression of COX-2, a protein implicated in pancreatic cancer 
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development (Cascinu et al., 2007; Hill et al., 2012; Yip-Schneider et al., 2000). Our 
collective data suggest that such studies may help guide identification of a subpopulation 
of pancreatic cancer patients that could derive therapeutic benefit from co-targeting MEK 
and CDK4/6.  
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FIGURES 
Figure 2.1
Figure 2.1: : Dual inhibition of MEK and CDK4/6 shows synergy in pancreatic cancer cell lines. (A) Evaluation of synergy in 
20 pancreatic cancer cell lines identifies a range of response to combination treatment. Synergy scores represent a consolidated 
quantitative measure of proliferation in response to 25 unique combinations of trametinib and palbociclib concentrations after being 
treated for 5 days, as calculated by Chalice software. Scores represent the mean of 2-4 biological replicates +/- standard error of the 
mean (SEM).  Genetic alterations for CDKN2A and KRAS are shown for each line.  (B) Synergy scores were median centered and 
expressed as the log2 difference from the median with a 95% confidence interval. (C) Synergy plots generated by Combenefit 
showing the interaction between trametinib and palbociclib are shown for the highest and lowest responder models (n=4, technical 
replicates), alongside the primary data from the same experiment showing the shift in the trametinib concentration response curve 
upon addition of 1 μM palbociclib for each line (n = 4, +/- SEM). Data shown are representative and consistent with replicate 
experiments. 
 1ATCC database, 2COSMIC (Forbes et al., 2010), 3Genetics of Pancreatic Cancer (Kern), 4(Souchek et al., 2014)  
*p.V487_P492>A, HD = homozygous deletion, methylated = promoter methylation, fs = frameshift mutation. p16 mutation D84G 
confers loss of function (Yarbrough et al., 1999). Inactivation of CDKN2A was determined via immunoblot (no detectable protein). 
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Figure 2.2 
  
Figure 2.2 : Cell cycle effects of CDK4/6 inhibition are enhanced by MEK inhibition in L3.6pl and UM59 cells. (A) Cell 
cycle analysis shows evidence for G1 arrest in cells treated with palbociclib and trametinib for 48 hours. (B) Cells were treated 
with 10 nM trametinib or 1 μM palbociclib, alone or in combination for the indicated time period. 
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Figure 2.3 
  
Figure 2.3: Single agent treatment with trametinib and palbociclib inhibits phosphorylation of Rb and 
ERK. (A) Concentration response of the effects of trametinib and palbociclib on Rb, ERK and cyclin D1 
after 5 days of treatment. (B) Concentration response curves showing effects of trametinib and palbociclib 
on the proliferation of two cell lines with high synergy score (L3.6pl & UM59) and two with the low synergy 
score (Panc10.05 & Bxpc-3). Data are representative of multiple experiments and expressed as mean +/- 
SEM, n = 4 per point, treatment duration of 5 days. (C) Concentration response curves showing effects of 
trametinib and palbociclib on the proliferation of two cell lines with high synergy score (L3.6pl & UM59) 
and two with the low synergy score (Panc10.05 & Bxpc-3). Data are representative of multiple experiments 
and expressed as mean +/- SEM, n = 4 per point, treatment duration of 5 days. 
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Figure 2.4 
 
Figure 2.4: Combination treatment is efficacious in vivo and correlates with decreased COX-2 
expression. (A) L3.6pl cells were implanted subcutaneously and treatment was administered once daily via 
oral gavage for 10 days (shaded region) or until the group mean reached 1000 mm3 (n = 5 per group). Tumors 
were harvested from a separate cohort on Day 7 (dotted line) for pharmacodynamic analysis. (B and C) 
Immunohistochemistry for Ki67 was performed and quantified (Immunoratio) in Figure B as a ratio between 
Ki67 stained nuclei and total nuclear area, while C shows representative images of treated tumors. (D) 
Heatmap generated from RPPA analysis of tumor lysates showing changes in protein expression. (E) RPPA 
results were verified via immunoblotting analysis for COX-2 and Pdcd4 expression. ** indicates p < 0.005, 
*** p < 0.0005, **** p < 0.0001, in comparison to combination arm. 
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Figure 2.5 
 
 
 
 
 
 
  
Figure 2.5: COX-2 expression is implicated in sensitivity to co-targeting of MEK and CDK4/6. (A) Immunoblotting analysis 
of FOXM1 expression in L3.6pl cells harvested after a 5-day treatment with the indicated conditions. (B) Six clones expressing 
the CMV driven hCOX-2 construct were compared to the parent L3.6pl cell line for expression of COX-2. (C) A clone shown to 
express constitutively high levels of COX-2 (C5) was compared to the parent line in a head-to-head in vivo study (n = 5 per 
treatment condition, treatment period is shaded). Tumor burden was monitored during treatment and T/C values are shown for 
all treatment conditions. (D) Lysates were collected multiple times from L3.6pl cells expressing either a control shRNA plasmid 
or COX-2 shRNA to confirm COX-2 knockdown. (E) Combenefit graphs showing a reduced synergistic response of L3.6pl cells 
expressing COX-2 shRNA. (F) This chart lists the mean synergy scores +/- SEM of each cell line derived from L3.6pl to test the 
role of COX-2. ns indicates p > 0.05, * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001, in comparison to combination 
arm. 
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Figure 2.6 
Figure 2.6: High expression of COX-2 correlates with greater relative benefit in the in vitro synergy screen 
and in tumor-bearing animals. (A) Expression of COX-2 in the panel of pancreatic cancer cell lines tested in the 
synergy screen. (B) In vivo studies were conducted in mice subcutaneously implanted with either UM59 (n = 4 per 
group), Panc-1 (n = 3 per group) or Panc10.05 (n = 5 per group) cells. Drugs were administered once daily via oral 
gavage for 10 days (shaded region) once tumors reached roughly 150-200 mm3. The percent treatment/control 
(%T/C) and ΔT/ΔC on the last day of treatment as well as tumor growth delay (calculated at 750 mm3 for UM59 and 
Panc-1, and 700 mm3 for Panc10.05) are shown for each in vivo experiment. * indicates p < 0.05, ** p < 0.005, in 
comparison to combination arm on last day of treatment. Panc10.05 p values indicated on lower right of graph and 
were calculated based on T/C values, as a negative ΔT/ΔC cannot be calculated accurately. If no p values were 
indicated, differences are not statistically significant. 
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Figure 2.7: Supplementary Figure 1 
Figure 2.7: Supplementary Figure S1: Impact of drug concentration and kinase inhibitor 
selection on synergistic response (L3.6pl model).  (A) Gross sensitivity of the pancreatic cancer 
cell line data set to combination treatment at the indicated concentrations is represented with box 
plots.  The median of the cell line panel is shown by a line with the corresponding number below the 
line. The whiskers represent the minimum and maximum points. Each point in the boxes represents 
the percent viability of one cell line to the indicated drug treatment and is representative of replicate 
experiments. (B) Synergy scores and Combenefit graphs are shown for L3.6pl cells treated with 
different MEK and CDK4/6 inhibitors. 
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Figure 2.8: Supplementary Figure 2 
Figure 2.8: Supplementary Figure S2: Effect of combination treatment on growth and protein 
expression in models eliciting high and low synergy scores. (A) Palbociclib concentration response curves 
for L3.6pl, UM59, Panc10.05 and Bxpc-3 (mean +/- SEM, n = 4 per point) with indicated concentrations of 
trametinib added to show potency of combination treatment. (B) Immunoblotting analysis of various proteins 
using lysates harvested from L3.6pl cells treated for 5 days. 
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Figure 2.9: Supplementary Figure 3 
 
Figure 2.9: Supplementary Figure S3: Evaluation of in vivo efficacy to the combination of trametinib 
and palbociclib in L3.6pl tumor-bearing animals. L3.6pl cells were implanted subcutaneously into the 
flank of nude mice (n = 3 per group) and once tumors reached ~150-200 mm3, animals were treated via oral 
gavage once daily with the indicated doses. Each point represents the mean +/- SEM of the group. T/C values 
were calculated on day 15. Vehicle vs Combination p < 0.05, all other groups not statistically significant 
(combination versus palbociclib p = 0.23, combination versus trametinib p = 0.08). 
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Figure 2.10: Supplementary Figure 4 
 
Figure 2.10: Supplementary Figure S4: Effect of combination treatment on COX-2 and Pdcd4 
expression. (A) RT-qPCR of COX-2 and Pdcd4 transcripts from treated L3.6pl and UM59 cells, expressed 
as mean +/- SEM (n = 4 per group, results combined from two separate experiments) relative to DMSO 
treated cells. (B) Protein expression changes in lysates collected from treated UM59 cells (5 days). (C) L3.6pl 
and UM59 cells were treated with both celecoxib and NS-398 over a wide range of concentrations. Data are 
expressed as mean +/- SEM (n = 8). Data are representative of two additional experiments. 
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Figure 2.11: Supplementary Figure 5 
 
Figure 2.11: Supplementary Figure S5: Effects of trametinib and palbociclib alone and in combination 
on growth and expression of various signaling proteins. (A) Concentration response curves for both L3.6pl 
and L3.6pl-C5 in response to trametinib and palbociclib (mean +/- SEM, n = 4 per point). (B) Trametinib 
concentration response curves for L3.6pl and L3.6pl-C5 (mean +/- SEM, n = 4 per point) with indicated 
concentrations of palbociclib. Data for both (A) and (B) are representative of three additional experiments. 
(C) Lysates were harvested from tumors of the animal study in Figure 5C on the last day of treatment and 
immunoblots of indicated proteins are shown. 
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Figure 2.12: Supplementary Figure 6 
 
  
Figure 2.12: Supplementary Figure S6: COX-2 expression at the RNA and protein 
level. (A) RT-qPCR of COX-2 in RNA harvested from the pancreatic cancer panel, 
showing expression of the panel in relation to Bxpc-3 which had the highest expression 
(mean +/- SEM, n = 3 per point). (B) Comparison of COX-2 expression in tumors 
harvested from vehicle control animals in L3.6pl (Fig. 4) and Panc10.05 (Fig. 6). Each 
band represents a tumor from a separate animal. 
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Appendix B 
 
Many people have contributed to the research studies presented in this chapter and their 
corresponding contributions are listed below. 
 
Conception and design: Maust, JM, Sebolt-Leopold, JS 
Methodology: Maust, JM, Frankowski-McGregor, CL 
RPPA analysis: Bankhead III, A, Maust, JM 
PDX models source: Crawford, H, Simeone, DM 
Synergy screening: Maust, JM 
Acquisition of data: Maust, JM, Frankowski-McGregor, CL 
Molecular biology: Maust, JM, Frankowski-McGregor, CL 
COX-2 pcDNA source: Smith. W 
Writing, review and/or revisions of manuscript: Maust, JM, Sebolt-Leopold, JS 
 
At the time of submission, Chapter 2 has been accepted to Molecular Cancer Therapeutics 
for publication.  
 
Maust, J.D., Frankowski-McGregor, C.L., Bankhead III, A., Simeone, D.M., 
Sebolt-Leopold, J.S. (2018). Cyclooxygenase-2 Influences Response to Co-
Targeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. 
Molecular Cancer Therapeutics. 
Data presented in Chapter 2 were preceded by the evaluation of MEK and CDK4/6 co-
inhibition in colorectal cancer and was published in Clinical Cancer Research. 
 
Ziemke, E.K., Dosch, J.S., Maust, J.D., Shettigar, A., Sen, A., Welling, T.H., 
Hardiman, K.M., Sebolt-Leopold, J.S. (2016). Sensitivity of KRAS-Mutant 
Colorectal Cancers to Combination Therapy that Co-targets MEK and CDK4/6. 
Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-15-0829 
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Chapter 3: Designing Experimental Therapeutics to Treat 
KRAS and BRAF Mutant Colorectal Cancer 
 
Abstract 
Agents targeting epidermal growth factor receptor (EGFR) have met with limited success 
in the clinical management of colorectal cancer (CRC). Mutations in KRAS, BRAF, and 
PIK3CA are important drivers of resistance to EGFR-targeted therapy. Conversely, EGFR-
mediated feedback mechanisms promote resistance to MEK inhibitor-based treatment of 
CRC by reactivating MAP kinase signaling. Our central hypothesis is that a dual small 
molecule inhibitor that potently and selectively targets only EGFR and PI3K, when 
combined with a MEK inhibitor, will be highly efficacious against subpopulations of 
BRAF mutant or KRAS mutant colorectal cancers that are dependent upon these kinase 
molecules to drive tumor progression. Employing a computational modeling approach, we 
exploited the known binding modes of structurally related ATP binding site inhibitors of 
EGFR and PI3K to design small molecules that simultaneously inhibit both kinases in a 
selective manner. To the best of our knowledge, the lead compound MTX-211, whose 
binding mode is flipped in PI3K compared to EGFR, represents a first in class selective 
inhibitor of these two critical oncogenic kinases. MTX-211 exhibits a favorable 
pharmaceutical and selectivity profile, possessing sub- to low nanomolar potency against 
both targets, >70% oral bioavailability, strong pharmacodynamic modulation of both 
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EGFR and PI3K signaling, and strong in vivo single agent efficacy against multiple 
BRAFmt and KRASmt colorectal cancer models.  
Introduction 
Agents targeting EGFR have met with limited success in the clinical management of 
colorectal cancer (CRC) and are limited to treatment of those patients whose tumors do not 
harbor mutations in KRAS or BRAF (Amado et al, JCO 2008; De Roock et al, Lancet 
Oncol, 2011; Karapetis et al, NEJM 2008).  Approximately 50% of colorectal malignancies 
are known to possess either a KRAS or BRAF mutation, conferring a poor prognosis.  The 
co-occurrence of PIK3CA mutations or loss of expression of the tumor suppressor PTEN 
further contribute to the inability of EGFR inhibitors to effectively treat these tumors 
(Atreya et al, Cancer Med, 2013; Jhawer et al, Cancer Res 2008; Liao et al, Clin Cancer 
Res 2012; Sawai et al, BMC Gastroenterol 2008).   Both EGFR and PI3K signaling have 
also been implicated in the resistance of KRAS mutant cancers to MEK inhibitor 
monotherapy (Caunt et al, Nature Rev Cancer, 2015; Mirzoeva et al, MCT 2013; Turke et 
al, Cancer Res 2012).  Thus, the design of a single molecule that could target both EGFR 
and PI3K compensatory signaling in response to MEK inhibition would be an attractive 
alternative to triple drug combination treatment strategies. This chapter explores the 
evaluation of MTX-211, a rationally designed small molecule inhibitor of EGFR and PI3K, 
two kinases that are importantly linked to KRAS signaling. 
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Materials and Methods 
Cell Culture and Inhibitors 
HCT-116 and RKO cells were obtained from the American Type Culture Collection 
ATCC).  HCT-116 cells were maintained in McCoy’s 5A media (Invitrogen) supplemented 
with 10% FBS (HyClone), 1% GlutaMax, (Invitrogen) and 1% Penicillin Streptomycin 
(Invitrogen).  RKO cells were maintained in EMEM media (Lonza) supplemented with 
10% FBS (HyClone), 1% GlutaMax, (Invitrogen) and 1% Penicillin Streptomycin 
(Invitrogen).  All cells were incubated at 37°C in 5% CO2. Cell line validation was 
performed by the University of Michigan DNA Sequencing Core using short tandem repeat 
analysis.  
Drugs 
MTX-211 was synthesized by Cayman Chemicals and trametinib was purchased from LC 
Laboratories.  For cellular studies, drugs were dissolved in DMSO at a concentration of 10 
mmol/L and stock solutions were stored at -20°C.  
Cell Viability Assay 
For growth inhibition analysis, cells were seeded in whitewalled/clear-bottom tissue 
culture treated 96-well plates and allowed to adhere for 24 hours followed by addition of 
growth media containing serial dilutions of MTX-211, trametinib, or both drugs in 
combination. Control wells received DMSO at a final concentration of 0.2%. Cells were 
incubated for 3 days in the continuous presence of drug or DMSO and viability was 
measured using CellTiter-Glo (Promega). Viability was calculated as a percentage of the 
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DMSO-treated cells. Four replicates were performed for each of the different drug 
treatment conditions. Data were modeled using a nonlinear regression curve fit with a 
sigmoidal dose–response using GraphPad Prism 6 (GraphPad Software). Synergy 
calculations were performed using Combenefit software (Cancer Research UK Cambridge 
Institute). 
Clonogenic Assay 
For each cell line, 500 cells were plated per well into 6-well plates, with six replicates per 
treatment condition.  The cells were allowed to attach overnight.  Cells were treated with 
MTX-211, trametinib, or the combination at the concentrations indicated in the figure 
legends.  Ten days later, the cells were fixed with 10% neutral buffered formalin (NBF) 
and the stained using 0.1% crystal violet. The colonies were counted using OpenCFU open-
access software (insert reference number). Quantification is presented as mean ± SEM. In 
assessing the different treatment conditions, a one-way ANOVA test was used for 
statistical analysis. 
Western Blots 
Cells or tumors were lysed in NP-40 lysis buffer [25 mmol/L Tris-HCl (pH 7.6), 150 
mmol/L NaCl, 1% Nonidet P-40, 10% glycerol, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, 
and protease and phosphatase inhibitors], rocked for 30 minutes at 4°C, and centrifuged at 
13,200 rpm for 20 minutes at 4°C. Protein concentration was determined by BioRad Protein 
Assays and lysates were subsequently subjected to SDS gel electrophoresis. Proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes and probed with primary 
antibodies recognizing p-EGFR tyr1068), EGFR, p-HER2 (tyr1248), HER2, p-AKT 
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(ser473), p-AKT (thr308), AKT, pERK1/2 (thr202/tyr204), ERK1/2, pS6K (ser235/236), 
S6K, and cleaved PARP (all from Cell Signaling Technology) and beta actin (Abcam). 
After incubation with anti-rabbit HRP-linked secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc.), proteins were detected using chemiluminescence 
(GE Healthcare). 
Xenograft Studies 
The colorectal PDX models were established as described previously (Ziemke et al., 2015). 
For the xenograft studies established from the PDX models, female 6- to 7-week-old NCR 
nude mice (CrTac:NCr-Foxn1nu from Taconic) were implanted subcutaneously with low-
passage PDX tumor fragments (30 mg) into the region of the right axilla. For the xenograft 
studies established from cell lines, the HCT-116 or RKO cells were injected (1 X 106 cells 
per injection) into the flanks of female 6- to 7-week old NCR nude mice. In both cases, the 
mice were randomized into treatment groups and treatments initiated when tumors reached 
100 to 200 mg. MTX-211 and trametinib were administered daily by oral gavage as a 
solution in 5% dimethyl sulfoxide and 95% polyethylene glycol and a fine suspension in 
0.5% HPMC with 0.2% Tween-80, respectively, based upon individual animal body 
weight (0.2 mL/20 g). Subcutaneous tumor volume and body weights were measured two 
to three times a week. Tumor volumes were calculated by measuring two perpendicular 
diameters with calipers and using the formula: tumor volume ¼ (length x width2)/2. For 
the single agent screening studies, mice were treated for the time period as indicated in the 
figure and euthanized following the last treatment. Percent treated/control (%T/C) was 
calculated by dividing the median treated tumor weight by the median control tumor weight 
and multiplying by 100 on the last day of treatment. A one-sided unpaired T-test was used 
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to assess differences between the vehicle control and the MTX-211 treated mice. For the 
lifespan assays, the mice were treated daily as indicated until their individual tumor 
burdens surpassed 1000 mg at which point the mice were euthanized.  Increase in lifespan 
was calculated by dividing the median increase in lifespan (days) by the median survival 
time of the vehicle control group.  A log-rank (Mantel-Cox) test was run to compare the 
difference in survival between the treatment groups. All procedures related to the handling, 
care, and treatment of animals were conducted in accordance with University of Michigan's 
Institutional Animal Care and Use Committee guidelines.  
Immunohistochemistry 
Tissues were fixed in 10% NBF, embedded in paraffin, and sectioned in accordance with 
standard procedures. Samples were processed by Daniel Long in the Crawford Lab at 
University of Michigan. The Ki67 antibody was obtained from Abcam (ab15580). The 
slides were scanned using a 3D Histotech Panoramic SCAN II.  Images were captured 
using CaseViewer software.  Images were taken with a Nikon E-800 microscope, Olympus 
DP71 digital camera, and DP Controller software. For quantification of staining, 
representative images were obtained from the stained slides at ×40 objective magnification 
for ImmunoRatio analysis. For each treatment condition (vehicle, trametinib, palbociclib, 
and combination), five representative fields of view from four individual tumors were 
analyzed. The images were analyzed using the basic mode in the ImmunoRatio software. 
Quantification is presented as mean ± SEM. In assessing the different treatment conditions, 
a one-way ANOVA test was used for statistical analysis.  
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Results 
MTX-211 binds to EGFR and PI3K in a flipped binding mode fashion 
MTX-211 emerged from a drug design campaign in the Leopold laboratory employing 
computational modeling to design small molecules that would selectively and 
simultaneously inhibit EGFR and PI3K.  The design of MTX-211 and structurally related 
analogs was based upon analysis of the known binding modes of closely related ATP 
binding site inhibitors of these kinases.  The x-ray crystal structure of erlotinib bound to 
EGFR (Stamos et al., 2002) shows the nitrogen at the 1-position of the quinazoline moiety 
forming a hydrogen bond with the amide nitrogen of MET793 (Fig. 3.1A).  Residues 
Leu792 and Gln791 form the backbone of the erlotinib binding pocket. In contrast, 
omipalisib (GSK2126458) bound to PI3Kγ (Knight et al., 2010) is flipped relative to the 
way in which erlotinib binds to EGFR with the nitrogen at the 1-position of the quinoline 
moiety forming a hydrogen bond with the hinge backbone of VAL882.  Whereas the 6-
position of the quinazoline ring of erlotinib points out towards solvent, the 6-position of 
omipalisib points towards the back of the ATP pocket of PI3Kγ towards a hydrophilic PI3K 
specificity pocket. The flipped binding mode of the quinazoline core between EGFR and 
PI3Kγ was leveraged to computationally design potent and selective dual inhibitors of both 
enzyme families, which lead to the discovery of MTX-211 (Figure 3.1B). Crystallization 
studies carried out with purified EGFR and PI3Kgamma have confirmed the postulated 
flipped binding mode of MTX-211 between these two targets (Figure 3.1C). 
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Biochemical profiling: MTX-211 is highly potent and selective against EGFR and 
PI3K 
MTX-211 possesses low or sub- nanomolar potency against purified EGFR and PI3Kα as 
reflected by IC50’s of 3.6 and 0.6 nM, respectively (Supplementary Fig. 3.5/1A).  Expanded 
testing against other HER and PI3K family members showed that MTX-211 also exhibits 
significant, albeit reduced, potency against HER2 and HER4, similar to the profile of 
erlotinib.  Furthermore, the ability of MTX-211 to strongly inhibit all PI3K isoforms as 
well as mTOR leads to a biochemical profile strikingly similar to that of copanlisib (Scott 
et al., 2016).  MTX-211 is highly selective for HER and PI3K family members as revealed 
by screening of a broad panel of >100 kinases, encompassing a diverse array of tyrosine, 
serine/threonine, and lipid kinases (Supplementary Table 3.1).  
Biological profiling of MTX-211 reveals strong activity in colorectal cancer models  
The anti-proliferative activity of MTX-211 against the NCI-60 panel was most pronounced 
for colorectal cancer models, where KRAS or BRAF is mutated in 5 of 6 cases and the 
median IC50 was 1110 nM (Fig. 3.2A; Supplemental Fig. 3.5/1B). In accordance with the 
strong activity of MTX-211 towards PI3K, PIK3CA was the only gene mutated in the NCI-
60 panel that correlated with sensitivity to MTX-211, with the most responsive half of the 
cohort containing all the PIK3CA mutations (Supplementary Fig. 3.5/1C). Evidence for 
dual cellular inhibition of EGFR and PI3K signaling was generated in both BRAF mutant 
RKO and KRAS mutant HCT-116 colorectal cells (Fig. 3.2B).  In both models, 
autophosphorylation of EGFRY1068 is effectively suppressed by MTX-211.  Consistent with 
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its biochemical profile, MTX-211 more strongly inhibits PI3K than EGFR as reflected by 
reduced pAKT expression at concentrations as low as 1 to 10 nM. 
Since the PI3K pathway is a major regulator of cyclin D1, cell cycle entry and has been 
reported extensively to inhibit apoptosis (Klein and Assoian, 2008; Li et al., 2008a; Liu et 
al., 2013; She et al., 2005; Shimura et al., 2012; Will et al., 2014), we anticipated that 
MTX-211 treatment would lead to cell cycle arrest and/or apoptosis.  A significant sub-G1 
population was induced in HCT-116 cells in response to MTX-211, indicative of apoptosis. 
This was confirmed by a time-dependent induction of cleaved PARP expression, which 
was also a concentration-dependent response (Fig. 3.2C; Supplementary Fig. 3.6/2A).  The 
cell cycle effects of MTX-211 mirrored those seen in response to the combination of 
omipalisib and erlotinib, consistent with its on-target effects. Pan-caspase inhibitor Z-
VAD-FMK prevented the emergence of the sub-G1 population and also cell death caused 
by MTX-211 over a 24 hour treatment. This suggests that the sub-G1 population predates 
apoptosis and cell death (Supplementary Fig. 3.6/2B). Z-VAD-FMK left cells arrested in 
G2/M phase, indicating that a G2/M arrest possibly forms a transition state into apoptosis 
in response to MTX-211. Importantly, these results are consistent with cells treated with 
comparator compounds omipalisib and erlotinib at equimolar concentrations. 
Pharmacodynamic profiling of MTX-211 confirms its dual inhibitory properties in vivo  
Treatment of mice with a single oral dose of MTX-211 results in an exposure (≈20 µM) 
that is roughly 2 logs higher than the cellular EC50’s required to impair EGFR and PI3K 
signaling (Supplementary Table 3.2).  In HCT-116 tumor-bearing animals, a single oral 
dose of 50 mg/kg MTX-211 was sufficient to strongly inhibit expression of activated EGFR 
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and AKT, indicative of its dual kinase inhibitory profile (Fig. 3.2D). This experiment 
further substantiated the induction of apoptosis seen in vitro, with a significant induction 
of cleaved PARP (Fig. 3.2D) 
MTX-211 is synergistic in combination with a MEK inhibitor 
The ability of MTX-211 to inhibit both EGFR and PI3K family members makes it an ideal 
candidate for combination with agents targeting the ERK pathway.  Resistance to MEK 
inhibition has been shown to be mediated by reactivation of HER family members, enabled 
in part by loss of an ERK-mediated inhibitory feedback phosphorylation on EGFR (T669) 
leading to activation of the PI3K/AKT pathway (Li et al., 2008b; Turke et al., 2012a). The 
ineffectiveness of MEK inhibitor monotherapy is fueled by strong induction of AKT 
activation, which is driven by increased phosphorylation and transcription of HER3 as well 
as the loss of feedback inhibition of EGFR. 
We hypothesized that MTX-211, by virtue of its dual ability to inhibit HER and PI3K 
family members, would target the multiple escape routes that lead to resistance to ERK 
pathway intervention (Fig. 3.3A). We found that expression of phosphorylated HER3 is 
effectively suppressed by 1 µM MTX-211 in both KRASMT and BRAFMT cells (Fig. 3.3B). 
MTX-211 also ablates upregulation of pHER3 expression that occurs in response to MEK 
inhibition in KRASMT cells (Fig. 3.3B, Supplementary Fig. 3.6/2C). Consequently, MTX-
211 acts to blunt the activation of AKT that ensues in response to trametinib treatment. 
Consistent with the observations of others (Turke et al., 2012b), we find that MEK inhibited 
KRASMT cells exhibit a reduction in the degree of phosphorylation of the T669 regulatory 
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site on EGFR (Fig. 3.3B), and further find that this reduction can be reversed by MTX-
211. 
Apoptosis occurring in response to MTX-211 increases upon co-treatment with trametinib, 
inversely correlating with the degree of phosphorylation of the serine112 site of the 
propapoptotic protein BAD (Fig. 3.3C).  A published study by She et al. presents support 
for this site being EGFR/MEK/ERK dependent, in contrast to the serine136 site, which is 
PI3K/AKT dependent (Fang et al., 1999; She et al., 2005). This finding led to the prediction 
that MTX-211 would prove synergistic in combination with ERK pathway intervention, 
which was borne out in clonogenic assays conducted with HCT-116 and RKO cells treated 
with MTX-211 and a number of MEK or ERK inhibitors (Fig. 3.3C, Supplementary Fig. 
2.7/3A). 
These data were further corroborated by the emergence of PI-/Annexin V+ and 
PI+/Annexin V+ populations in cells treated with MTX-211. Comparator compounds 
omipalisib and erlotinib elicited a similar response at concentrations that inhibit pAKT and 
pEGFR equally (Supplementary Fig. 3.7/3B). 
MTX-211 in combination with trametinib is highly efficacious in patient-derived 
colorectal cancer models 
Preclinical proof-of-concept for the clinical advancement of MTX-211 emerged from a 
pilot mouse trial of a diverse panel of KRASMT colorectal cancer patient-derived 
xenografts.  Five models were selected to provide heterogeneity of KRAS mutations 
(G12D, G13D and G12C) and included one BRAFMT model, UM CRC 14-929 
(Supplemental Table 3.3). Cohorts were included to evaluate in vivo efficacy of MTX-211 
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alone and in combination with trametinib. Only one model received no benefit from MTX-
211 treatment and one model responded equally well to MTX-211 and the combination 
(Fig. 3.4). 
The remaining three models all responded favorably to the combination of MTX-211 and 
trametinib, as evidenced by the incidence of objective responses or an increase in 
progression free survival (PFS) >100% (Fig. 3.4). Trametinib as a single agent was mostly 
inactive in all five models.  No significant body weight loss was observed in response to 
the combination of MTX-211 and trametinib over the course of these studies, exceeding 
120 days of daily dosing in some cases (Supplementary Fig. 3.8/4).  MTX-211 was also 
efficacious in combination with trametinib in fully immune competent animals implanted 
with KRASMT CT-26 tumors (Supplemental Fig. 3.9/5). Furthermore, MTX-211 was found 
to be highly efficacious in combination with trametinib against the BRAFMT CRC model. 
UM CRC 14-929 displayed a 285% increase of lifespan in animals treated with 
combination therapy, a noteworthy decrease in Ki67 staining and favorable target potency 
(Supplementary Fig. 3.10/6A, B, C). In addition, comparing MTX-211 and trametinib to 
MTX-211 and binimetinib (MEK) or alpelisib (PI3K), cetuximab (EGFR) and trametinib 
showed that MTX-211 and trametinib/binimetinib led to substantially better activity than 
the comparator compounds (Supplementary Fig. 3.10/6D). This forms the basis for 
preclinical proof-of-concept in comparison to current clinical candidates and approved 
agents targeting EGFR and PI3K. 
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Discussion 
The rationale for targeted therapy rests upon the assumption that certain signaling nodes or 
kinases are critical for growth. Preclinical and clinical findings have shown that, while this 
may be true, critical adaptive signaling methods exist to enforce redundancy in these 
pathways. The emergence of dual and even triple combination studies foreshadow a field 
that relies upon inhibiting several kinases that in sum inhibit signaling and bypass feedback 
mechanisms. While employing several inhibitors would fulfill this requirement, balancing 
adverse events in the clinic precludes many of these combinations. In this study, we report 
a dual inhibitor of EGFR and PI3K, two critical growth kinases that have and are a part of 
adaptive signaling. Inhibition of both targets with a single molecule decreases the risk of 
adverse drug-drug interactions and offers the attractiveness of a single pharmacokinetic 
profile for optimization of a dosing regimen.  
MTX-211 was computationally designed based off the known binding nodes of closely 
related ATP binding site inhibitors omipalisib and erlotinib. These inhibitors share a 
common quinazoline core that are spatially flipped within their respective kinase. 
Crystallization studies confirmed the flipped binding mode of MTX-211 to its two targets. 
Low to sub- nanomolar potency is observed against EGFR and PI3K (3.6 and 0.6 nM).  
MTX-211 displays broad activity against cancer models from the NCI-60 panel, with the 
most potent median activity against colorectal cancer. While it is not expected for an 
EGFR-based therapy to directly show benefit in KRAS and BRAF mutant disease, it is a 
critical node through which adaptive signaling to MAPK pathway inhibition is directed 
(Corcoran et al., 2012; Li et al., 2008b; Turke et al., 2012a). We report that in combination 
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with MEK inhibition, not only is growth signaling inhibited and tumor growth inhibition 
observed, but anticipated and observed feedback activation is targeted. Reduction in 
EGFRT669 is observed in response to MEK inhibition in CRC models, as well as 
upregulated transcription and phosphorylation of HER3. MTX-211, by inhibiting EGFR 
and PI3K activity, is poised to negate these acute adjustments in the growth signaling 
network. 
EGFR-based therapies are also limited in their ability to target KRAS and BRAF mutant 
disease due to the common co-occurrence of PIK3CA mutations or loss of tumor 
suppressor PTEN. Dual inhibition of EGFR and PI3K can therefore target downstream 
mutations that would normally preclude a patient from EGFR-based therapy. 
Circumstantial evidence supporting activity in PIK3CA mutant cells can be found in the 
mutational profile of the responsive NCI-60 panel models. Every model with a PIK3CA 
mutation was more responsive than the median of the panel, while no other mutation 
correlated with activity in the panel. 
MTX-211 displays anti-tumor activity in models in this report, primarily through the 
induction of apoptosis. Importantly, the anti-tumor effect of MTX-211 is predicated upon 
its ability to induce apoptosis, as a pan-caspase inhibitor Z-VAD-FMK was able to negate 
its effects. Furthermore, a G2/M arrest appears to be an important transition state to an 
apoptotic state. If the effects of this agent were purely growth inhibitory, a prolonged G1 
or G2/M arrested state would be expected. Instead, a dual-arrested G1-G2/M transitory 
state precedes induction of sub-G1, PI-/Annexin V+ and PI+/Annexin V+ populations. 
These characteristics raise the possibility that additional suitable combination agents that 
target the cell cycle in G1 or G2/M could prove synergistic with MTX-211. 
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The pharmacokinetic profile of MTX-211 is favorable, with exposures in vivo exceeding 
cellular EC50’s required to inhibit EGFR and PI3K. These doses also elicit favorable 
pharmacodynamics, with a single, tolerated oral dose inducing cleaved PARP and 
inhibiting pAKT and pEGFR. In vivo activity also demonstrates substantial preclinical 
proof-of-concept in six CRC PDX models.  
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Figures 
Figure 3.1 
  
Figure 3.1: X-ray crystal structure of MTX-211 bound to EGFR and PI3K. (A) X-ray crystal structures 
of erlotinib bound to the EGFR kinase domain (1M17) and omipalisib bound to PI3K gamma (3L08) left and 
right respectively.  Figure 1B, x-ray crystal structures of MTX-211 bound to the kinase domain of EGFR 
(left) and PI3K gamma (right).  Figure 1c ribbon diagram of MTX-211 bound to kinase domain EGFR (left) 
and PI3K gamma (right).  
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Figure 3.2 
Figure 3.2: Response of the NCI-60 panel to MTX-211 and the effects of MTX-211 in vitro. (A) The NCI-60 panel 
response to MTX-211 median centered by the logIC50. (B) Immunoblots of various proteins related to MTX-211 mode 
of action and their response to MTX-211 treatment in BRAF mutant model RKO and KRAS mutant model HCT-116. 
(C) Cell cycle effects of MTX-211 and comparator compounds in HCT116. Below this, time dependent apoptosis 
study. (D) Single oral dose of MTX-211 in nude mice implanted with HCT-116 cells. Tumors were harvested 2 hours 
after single oral dose and immunoblotted for various proteins to examine pharmacodynamics of MTX-211. 
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Figure 3.3 
 
Figure 3.5: Effects of MTX-211 in combination with MEK inhibition. (A) Signaling diagram showcasing 
common adaptive signaling in response to MEK and MTOR signaling and how MTX-211 can target these 
mechanisms. (B) Immunoblots showcasing the ability of MTX-211 to target these resistance mechanisms, 
namely HER3 and pEGFR T669. (C) Clonogenic assays and immunoblots of HCT-116 and RKO cells treated 
with MTX-211, trametinib and a combination of the two. 
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Figure 3.4 
 
  
Figure 3.6: In vivo activity of combination therapy. Four UM CRC PDX models were evaluated for 
activity against trametinib, MTX-211 and combination therapy. Tumors were implanted subcutaneously 
and treated via oral gavage at the indicated doses once tumors reached ~150 mm3, with cohorts consisting 
of at least five animals in each treatment group. Efficacy was evaluated by an increase in lifespan (ILS) and 
statistics are shown on graph. 
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Figure 3.5 / Supplementary Figure 1 
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Figure 3.8: Target potency and 
response of NCI-60 panel to MTX-211 
treatment. (A) Concentration response 
curves showing target potency against 
PI3K and EGFR in purified enzyme 
assays. (B) The NCI-60 panel was sorted 
by tumor subtype and the median IC50 of 
MTX-211. (C) NCI-60 panel sorted by 
sensitivity to MTX-211 with listed gene 
mutations. 
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Figure 3.6 / Supplementary Figure 2 
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Figure 3.6: MTX-211 induces apoptosis in cells and blocks reactivation of pHER3 in response 
trametinib treatment. (A) Concentration-dependent titration of cleaved PARP induction in HCT-116 and 
RKO cells. (B) Cell cycle analysis of MTX-211 and comparator compounds show a similar induction of a 
sub-G1 population which is blocked by pan-caspase inhibitor Z-VAD-FMK. (C) KRASMT pancreatic 
adenocarcinoma PDX model UM59 treated with trametinib and MTX-211, with immunoblots showcasing 
reactivation of pHER3 and pAKT by trametinib treatment.  
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Figure 3.7 / Supplementary Figure 3 
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Figure 3.7: Discovery of synergy between MTX-211 and trametinib. (A) Synergy between MAPK pathway 
inhibitors and MTX-211 shown with synergy heatmaps generated with Comebenefit. (B & C) PI/Annexin V staining 
in HCT-116 cells examining the effects of trametinib and MTX-211 in comparison to erlotinib, omipalisib and 
trametinib at bioequivalent concentrations. Similar apoptosis is observed at these concentrations, consistent with the 
shared mechanistic basis of these inhibitors. 
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Figure 3.8 / Supplementary Figure 4 
 
Figure 3.8: In vivo efficacy and safety plots of combination therapy. Trametinib and MTX-
211 were evaluated as single agents and in combination for efficacy and dose tolerance. These 
plots are an alternate way of visualizing the in vivo graphs presented in Fig. 3.4. No significant 
body weight loss was observed in these studies as shown in the second column. 
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Figure 3.9 / Supplementary Figure 5 
  
Figure 3.9: In vivo efficacy of MEK and MTX-211 combinatorial treatment in immune competent 
mice of KRASMT mouse model CT-26. 
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Figure 3.10 / Supplementary Figure 6 
 
  
Figure 3.10: Activity of combination treatment of BRAF V600E model UM CRC 14-929. (A) 
Combination treatment showed substantial in vivo activity in this model, with a 285% ILS. Treatment was 
tolerated well by animals. (B) Immunoblots of lysates generated from harvested tumors show combination 
treatment decreases MAPK and PI3K signaling effectively, as well as ERK downstream target FOXM1. (C) 
Ki67 staining from the same harvested tumors mirrored the efficacy measurements. (D) In vivo comparator 
study in the UM CRC 14-929 model show equal if not better activity of MTX-211 and trametinib in 
comparison to similar compounds. 
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Supplementary Table 3.1 
 
 
  Table 3.1: Inhibition of a general kinase panel by MTX-211. 
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Supplementary Table 3.2 
 
  
Table 3.2: Pharmacokinetics of MTX-211. 
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Supplementary Table 3.3 
 
 
  
Table 3.3: PDX models from University of Michigan used in this report. 
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Appendix B 
 
Many people have contributed to the research studies presented in this chapter and their 
corresponding contributions are listed below. 
 
Conception and design: Maust, JM, Sebolt-Leopold, JS, Whitehead, CE, Ziemke, EK 
Computational chemistry: Whitehead, CE 
Animal studies: Mumby, RM, Ziemke, EK 
PDX models source: Hardiman, JM, Sebolt-Leopold, JS 
Acquisition of data: Frankowski-McGregor, CL, Ku, JB, Maust, JM, Mumby, RM, 
Whitehead, CE, Ziemke, EK 
X-ray crystallography: Ohren, JF, Viola, R, Whitehead, CE, Young, M 
Writing, review and/or revisions of manuscript: Maust, JM, Sebolt-Leopold, JS, 
Whitehead, CE, Ziemke, EK   
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Chapter 4: Discussion and Future Directions 
 
Prior to 1975, cytotoxic agents were all that was available for cancer therapy. Tamoxifen 
was the first hormonal anti-cancer drug, and hormonal agents have grown since then to 
account for approximately 20% of all cancer treatment drugs (Savage, 2012; Savage, 
2013). The time range from 1980-2000 saw an increasing amount of diversity in the content 
of approved drugs and the most prolific period of drug approval, with introduction of 
hormonal agents, new cytotoxics, and a few targeted therapies. It wasn’t until after 2000 
that a new era of drug discovery came, with the introduction of monoclonal antibodies, 
kinase inhibitors and other targeted therapies. In fact, from 2010-2014, the largest increase 
in novel drugs were kinase inhibitors, with 13 new inhibitors introduced to the market 
(Savage and Mahmoud, 2015). 
Following the introduction of these novel targeted therapies, the field began to think of 
cancer treatment not only in terms of tissue of origin, but the genetic background of cancer 
and the mutations driving oncogenesis. This in turn led to the concept of precision 
medicine, wherein individualized treatment plans are tailored to the mutations present in a 
particular tumor, regardless of tissue of origin (2017; Mateo et al., 2018). This has become 
more prevalent due to the significant decrease in costs of genomic sequencing, as well as 
an increase in “big data” projects that emphasize the power of bioinformatics in discovering 
trends in large patient datasets and in informing treatment decisions. These precision 
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medicine approaches de-emphasize subjective treatment decisions and aim to place 
decision making that is based on similar data from large patient cohorts. 
RAS mutations occur in 30-40% of all cancer and are a prime target for precision medicine 
approaches, although they have proven especially difficult to treat due to the absence of 
direct inhibitors and the lack of efficacy in inhibiting downstream effectors. Therefore, 
novel therapies for the treatment of RAS mutant disease are needed to help inform 
precision medicine approaches. 
Historically, while inhibition of RAS signaling has focused on inhibition of downstream 
effectors as single agents, inhibition of multiple different downstream effectors in 
combination has emerged as essential for addressing the compensatory signaling that arises 
in response to monotherapies.  The design of combination treatment approaches have been 
empowered by a better understanding of the feedback regulatory mechanisms that govern 
pathway output.  
MAPK pathway inhibitors have been approved in melanoma and include vemurafenib 
(BRAF), dabrafenib (BRAF) and trametinib (MEK). However, many of these agents 
prolong rather than ensure survival. For indications such as colorectal, MAPK pathway 
inhibitors have not been as successful, with approved therapies limited to EGFR-based 
inhibitors cetuximab and panitumumab. While these MAPK pathway inhibitors have been 
approved, they are contraindicated in patients with KRAS mutations, as EGFR inhibitors 
have shown a lack of efficacy in a KRASmt setting (Douillard et al., 2013). These agents 
are therefore limited to the treatment of EGFR-expressing, metastatic colorectal cancer that 
are KRASwt. The situation is similar for pancreatic cancer, where erlotinib, an EGFR 
inhibitor, was approved for the treatment of pancreatic cancer in combination with 
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gemcitabine. It was approved based on clinical trial results showing that median overall 
survival improved from 5.91 to 6.24 months with gemcitabine alone compared to 
gemcitabine and erlotinib in combination, respectively (Amanam and Chung, 2018). These 
modest improvements in outcome highlight the need for better therapeutics, as erlotinib 
was only improved based on this improvement due to the critical lack of effective 
therapeutics in the area. 
Co-targeting MEK and CDK4/6 
The lack of agents for the treatment of KRASmt colorectal and pancreatic cancer forms the 
rationale for MAPK-based combination therapies discussed in this dissertation. The first 
of these discussed was co-targeting MEK and CDK4/6 for the treatment of pancreatic 
cancer. The rationale for evaluating this combination was based on several factors outlined 
in the introduction of Chapter 2. Briefly, the high mutation rate of KRAS and CDKN2A is 
conducive to a combination therapy targeting the signaling consequences of these 
mutations (Figure 4.1 and Figure 4.2). Furthermore, additional evidence for this 
combination has been shown in studies showing synthetic lethality between KRAS and 
CDK4/6 (Mao et al., 2014; Puyol et al., 2010). CDK4 was also identified as a key driver 
of an alternative phenotype when comparing genetic ablation of mutant NRAS to the same 
cells treated with a MEK inhibitor instead (Kwong et al., 2012). 
A synergy-based screen was carried out in order to evaluate the efficacy of this dual-
targeted therapy in pancreatic cancer. A high degree of synergy was found in two 
adenosquamous carcinoma pancreatic cell lines, L3.6pl and UM59. This synergy was 
accompanied by high expression of COX-2, which was ablated by the introduction of 
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CMV-driven COX-2 gene expression as well as shRNA targeting COX-2. This led to the 
conclusion that high levels of COX-2 expression could potentially serve as a biomarker of 
exceptional response to combination therapy in pancreatic cancer. COX-2 has been 
extensively studied for its role in driving inflammation and carcinogenesis in pancreatic 
cancer as well as other cancers (Hawk et al., 2002; Hill et al., 2012; Ogino et al., 2008; 
Okami et al., 1999). It appears that pancreatic cancer cell lines in which COX-2 expression 
is elevated indicates a cellular context which is particularly sensitive to the effects of co-
targeting MEK and CDK4/6. 
Figure 4.1: Genetic aberrations predisposing pancreatic cancer to dual inhibition of MEK and CDK4/6 
and the signaling implications of these mutations. 
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The exact reason for these results is unclear, although we hypothesize that transcriptional 
control of COX-2 by MEK and CDK4/6 occurs through their direct control of the COX-2 
transcriptional regulator FOXM1. CDK4/6 phosphorylation controls stability of FOXM1 
(Anders et al., 2011) and activity and cellular localization is controlled by ERK 
phosphorylation as well (Ma et al., 2005b). In addition to these data, CDKN2A, which 
encodes for endogenous inhibitor CDK4/6 p16, also encodes p14. CDKN2A is deleted in 
the majority of cases of pancreatic cancer, which means loss of both these proteins. p14, 
has a role in regulating E3 ubiquitin-protein ligase MDM2 which itself regulates p53 
protein levels (Kumamoto et al., 2004; Lohrum et al., 2000). In addition, it has also been 
shown to directly bind and regulate FOXM1 due to the presence of two independent 
MDM2 binding domains (Pandit and Gartel, 2015; Quan et al., 2013). Therefore, in 
pancreatic cancer, not only do ERK and CDK4/6 play a role in regulating FOXM1, but 
there is an additional role for p14, which is itself not present in the majority of cases due 
to the deletion of CDKN2A. These considerations serve as suggestive circumstantial 
evidence for the ostensible role of combination therapy in targeting and reducing 
expression of FOXM1 and in turn COX-2. 
While FOXM1 is potentially implicated in the activity of MEK and CDK4/6 combination 
therapy, there exist other potential mechanisms of regulation behind COX-2. Reports 
indicate that COX-2 co-localizes at the plasma membrane with caveolin-1, a component 
critical for formation of plasma membrane caveolae (Liou et al., 2001; Perrone et al., 2007). 
These caveolae can function as signaling hubs, wherein they can be critical for the 
formation of lipid rafts as well as entry of signaling pathway components into these 
caveolae invaginations (Boscher and Nabi, 2012; Quest et al., 2008). In this way, close 
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proximity of the components of various signaling pathways can modulate pathway 
expression as well as gate potential directions for that signaling. Furthermore, localization 
to lipid rafts and plasma membrane location can modulate proximity to membrane bound 
tyrosine kinase receptors and gate signaling further in this way. It is possible that co-
localization MAPK-pathway components with COX-2 and its effector prostaglandins and 
in turn their effectors can form a signaling loop. COX-2 leads to the production of 
Figure 4.2: Extracellular growth signals are required for activation of MAPK and PI3K signaling in a 
normal setting. Mutation and overexpression of HER family members and RAS leads to malignant growth, 
which leads to gene expression and growth changes. 
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prostaglandins, which themselves activate the EP1-4 family of receptors. EP4 signaling 
has been shown to transactivate EGFR through Src-mediated phosphorylation minutes 
following treatment of cells with PGE2, which was blocked by an EGFR inhibitor or an 
EP4 inhibitor, with other studies corroborating these results (Buchanan et al., 2003; Kim 
et al., 2010; Pai et al., 2002).  
Furthermore, the role of COX-2 in angiogenesis has been noted (Huang et al., 2013). Given 
the downregulation seen, it is possible that combination treatment leads to activity partly 
through inhibition of angiogenesis in the developing tumors. I have anecdotal evidence 
from the L3.6pl animal study, in which tumors were harvested for RPPA analysis. The 
tumors from combination treated animals were paler than tumors from control and single 
agent groups and appeared to have less blood vessel innervation. However, at the time, 
pictures were not taken, as it did not appear important. 
Caveolin-1 
 Caveolin-1 has been implicated in protein degradation of COX-2 (Chen et al., 2010). 
Caveolin-1 null mice showed higher expression of COX-2 and deletion of the C-terminus 
of COX-2 (which is distinct from COX-1), decreased both binding between the two and 
the ability of caveolin-1 to reduce COX-2 expression. In the studies in Chapter 2 showing 
CMV-driven COX-2 decreased activity of combination therapy, there still existed 
significant decreases in COX-2 expression, presumably both from endogenous COX-2 still 
present as well as the ability of caveolin-1 to decrease COX-2 protein. Considering that the 
RPPA dataset showed a modest increase in caveolin-1 in combination treated tumors 
(Chapter 2), the role of caveolin-1 and signaling caveolae cannot be discounted and should 
be considered for future studies. The significance of this possibility is that efficacy of 
 97 
 
combination therapy could be dependent on co-localization of COX-2 with MEK, CDK4/6 
and/or kinase suppressor of RAS (KSR), a complex needed for MAPK signaling 
(Morrison, 2001; Nguyen et al., 2002; Razidlo et al., 2009; Roskoski, 2012). While 
signaling between all of these distinct pathways is assumed to occur in disparate locations 
of the cell, emerging evidence suggests that there may be more to regulation of these 
pathways than simple protein partners and linear signaling.  
Pdcd4 
In addition to regulation of COX-2, Pdcd4 was the other protein found to be most regulated 
by combination therapy upon RPPA analyses. This protein was recently discovered and the 
complete function is unknown, although a role in inhibiting progression of cancer and 
regulation by AKT has been discovered (Afonja et al., 2004; Kang et al., 2002; Leupold et 
al., 2007; Palamarchuk et al., 2005; Zhang and DuBois, 2001; Zhen et al., 2016). Among 
these studies, it was found that decreased expression of this protein correlated with 
increased invasiveness and progression of cancer. It is telling that an increase in protein 
expression of Pdcd4 was found in the tumors of animals treated with combination therapy, 
suggesting the initiation of cell death signaling and a possible tumor suppressor role. 
However, no increase in apoptotic proteins PARP, caspase-3, 7 or 8 was observed 
concurrently. As mentioned in Chapter 2, this tumor suppressor has been found to be in 
part responsible for the anti-cancer effects of COX-2 inhibitor NS-398 in a study looking 
at colorectal cancer, suggesting a possible link to the current study, wherein Pdcd4 
expression was increased alongside a decrease in COX-2 (Zhang and DuBois, 2001). To 
further strengthen this correlation, Pdcd4 has also been shown to negatively regulate gene 
expression by inhibiting Sp1/Sp3 binding at important motifs, which has implications for 
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the current study seeing as FOXM1 cooperates with Sp1 to promote COX-2 expression 
(Leupold et al., 2007). While no conclusive mechanistic insights come from these 
observations, many of these proteins have roles suggestive of mutual regulation. 
Emerging observations in the field 
In a manuscript published in 2014, Franco et al. conducted studies to screen for pathway 
selective inhibitors that show favorable activity in combination with CDK4/6 inhibitors 
(Franco et al., 2014). In this study, the observation was made that cyclin E expression was 
increased in cells treated with CDK4/6 inhibitors. At the time, aberrant induction of cyclin 
E was considered a targeted symptom of CDK4/6 inhibition and it was observed that 
shRNA knockdown of cyclin E and inhibitors that blocked induction of cyclin E showed 
synergy with CDK4/6 inhibitors. Beyond this observation, this group has not published 
any additional insights concerning this phenomenon. In fact, in 2016, Franco et al. reported 
the upregulation of cyclin D in response to CDK4/6 inhibition, with no mention of cyclin 
E (Franco et al., 2016). Both studies were conducted in models of pancreatic cancer, and 
the group collaborates with a surgeon at their institution for the establishment of PDX 
models of pancreatic cancer, in which they’ve identified CDK4/6 inhibition as a viable 
therapy for pancreatic cancer (Witkiewicz et al., 2015a; Witkiewicz et al., 2015b). Other 
than these two studies, there is a gap in the literature concerning the paradoxical 
upregulation of cyclin D/E in response to CDK4/6 inhibition. 
Palbociclib (Ibrance®) was given accelerated approval by the FDA in 2015 based on 
results from PALOMA-1, a phase 2 randomized, open-label clinical trial evaluating 
palbociclib in combination with letrozole for the treatment of postmenopausal, ER+, 
HER2- breast cancer (Finn et al.). PALOMA-2 and PALOMA-3 were phase 3 double-
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blind, randomized, clinical trials evaluating palbociclib in combination with letrozole (Finn 
et al., 2016) or fulvestrant (Cristofanilli et al., 2016), respectively. PALOMA-1 and 
PALOMA-2 both had biomarker cohorts, wherein certain predicted biomarkers were 
analyzed for their predictive ability. In PALOMA-1, a cohort of patients was required to 
contain amplification of cyclin D1, loss of p16 (CDKN2A), or both. In PALOMA-2, ER, 
Rb, p16, cyclin D1 and Ki67 were the biomarkers selected. In both studies, no significant 
predictive ability of cyclin D1 amplification or p16 loss was found, which runs counter to 
the fundamental assumption that these genetic alterations are necessary for activity of 
CDK4/6 inhibition. These negative results in biomarker analyses cause some confusion 
due to the fact that rational design of CDK4/6 inhibitors was predicated on its ability to 
restore functionality of p16 loss, which is the second-most mutated gene in human cancer 
(Liggett and Sidransky, 1998; Yarbrough et al., 1999). 
While neither cyclin D1 amplification or p16 loss can predict activity of CDK4/6-based 
combination therapy, emerging evidence from the PALOMA-3 trial revealed that high 
cyclin E expression can help predict response to palbociclib in metastatic breast cancer 
(Turner et al., 2018). Therefore, the only biomarker to date determined to predict for 
activity to palbociclib other than the presence of Rb is cyclin E, not p16 loss or cyclin D 
amplification. This fact brings us back to the phenomenon observed in pancreatic cancer 
in response to palbociclib treatment which upregulates cyclin D and E. It is important to 
first note that cyclin E is dispensable for mouse development and is not necessarily required 
for proliferation of all cell types, as commonly assumed (Geng et al., 2003). In fact, cyclin 
E deficient cells lack the ability to exit G0 to S, presumably due to the ability of cyclin E-
CDK2 complex to load mini-chromosome maintenance (MCM) proteins at origins of 
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replication (ORC). Furthermore, cyclin E-deficient cells resist oncogenic transformation. 
It would follow that overexpression of cyclin E promotes oncogenic transformation, as has 
been observed, notably in breast cancer (Furstenthal et al., 2001; Gao et al., 2013; Lunn et 
al., 2010; Matsumoto and Maller, 2004; Skalicky et al., 2006). 
The most likely explanation for the increase in expression of cyclin D and E in response to 
CDK4/6 inhibition is the loss of transcriptional regulator FOXM1, as was seen in Chapter 
2 upon treatment with CDK4/6 inhibition as well as combination therapy. FOXM1 is a 
critical regulator of cell cycle genes Skp2 and Cks1, which form part of the SCF ubiquitin 
ligase complex that degrades the G1 cyclins as well as the cyclin dependent kinase inhibitor 
(CKI) proteins p21 and p27 (Vodermaier, 2004; Wang et al., 2005). The lack of SCF 
complex degradation capacity likely leads to an accumulation of cyclin D/E and CKIs p21 
and p27. In addition to this, CKIs p21 and p27 are not only inhibitors of the complex 
activity, but are also critical for activation of the cyclin D-CDK4/6 and cyclin E-CDK2 
complexes due to the nuclear localization sequences on p21 and p27 which are not present 
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on CDK4/6 and CDK2 (Bockstaele et al., 2006; Cheng et al., 1999; Child and Mann, 2006). 
Therefore, the accumulation of cyclins D and E as well as p21/p27 is likely caused by an 
inability of the cell to generate the necessary components to degrade them, as the cell is 
permanently stuck in late G1 due to the presence of CDK4/6 inhibition. Increases in p21 
and p27 can be seen in Chapter 2 in response to treatment, and unpublished data generated 
in the Leopold Lab point not only to increases in cyclins D and E but also an increased 
association with their cognate CDKs in immunoprecipitation experiments. An increased 
association between cyclin D and CDK4 and cyclin D and p21 is also observed. This lends 
credence to the hypothesis that cells are permanently stuck in G1 due to the presence of 
Figure 4.3: CDK4/6-cyclin D complex signaling has been implicated in resistance to HER2-targeted 
therapies. Resistance through this complex leads to inhibition of TSC1/TSC2 and activates MTOR 
signaling, which HER2 normally activates. 
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these associated and inhibited complexes and the inability of the cell to degrade them and 
progress to S phase. 
The observation that increased expression of cyclin E could predict for sensitivity to 
palbociclib in PALOMA-3 may or may not be related to the previous observations made 
regarding accumulation of cyclin E. The most likely explanation is that they are unrelated 
to each other. Cyclin E is the last critical regulator of the G1 S transition, as cyclin E 
mediates the transition past the G1 restriction point and further regulates MCM loading and 
ORC formation (Ferguson and Maller, 2008; Geng et al., 2007; Geng et al., 2003; Liu et 
al., 2000; Lunn et al., 2010). Higher expression of cyclin E likely forces DNA replication 
through phosphorylation and inactivation of Rb in cells that would otherwise senesce or 
stall at the G1 DNA damage checkpoint. This is consistent with reports that low molecular 
weight isoforms of cyclin E in breast cancer lead to increased genomic instability and 
tumorigenesis due to the higher affinity of LMW cyclin E for CDK2 (Duong et al., 2012; 
Loeb and Chen, 2012; Nanos-Webb et al., 2012; Wingate et al., 2009). It seems that the 
ability of cyclin E to predict for palbociclib activity therefore arises from the ability of 
CDK4/6 inhibition to interrupt this uncontrolled cell division at the checkpoint 
immediately prior to cyclin E-CDK2, or to force cells into G0. The ability of cyclin E to 
promote tumorigenesis is further supported by elegant studies showing CDK2 to be a 
critical mediator of the cell decision in mitosis to continue proliferating or to enter a state 
of quiescence (Spencer et al., 2013). 
Tuberin Sclerosis Complex (TSC1/TSC2) 
CDK4/6 inhibition has been extensively studied for the treatment of breast cancer in 
combination with letrozole and fulvestrant, as covered in the previous section. Recently 
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however, it was reported that resistance to HER2 targeted therapy in breast cancer was 
mediated by cyclin D-CDK4 (Goel et al., 2016). This group showed that CDK4/6 not only 
suppresses Rb phosphorylation, but also plays a role in de-activating TSC1/TSC2 through 
phosphorylation, which has been known for some time (Franco et al., 2016; Huang and 
Manning, 2008). Inhibition of CDK4/6 through use of clinical inhibitors therefore led to 
activation of TSC1/TSC2, which in turn attenuates mTOR activity (Ma et al., 2005a). With 
EGFR/HER2 inhibition, CDK4/6 inhibition therefore increases activity by participating in 
reduction of TSC1/TSC2 phosphorylation, which attenuates mTOR activity further and 
consequently helps relieve feedback inhibition of the HER family members. 
In relation to the current project, the possibility that co-targeting MEK and CDK4/6 
modulates the AKT-MTOR axis is interesting. It has been reported that cyclin D by itself 
regulates the TSC complex, irrespective of CDK4/6 binding (Zacharek et al., 2005). A 
mutant cyclin D protein that is unable to bind the CDK complex negatively regulates TSC 
expression (Zacharek et al., 2005). Therefore, the previously mentioned finding that cyclin 
D and cyclin E expression is increased in response to CDK4/6 inhibition suggests that a 
regulatory role in the AKT-MTOR axis exists. This role could lead to negative regulation 
of TSC1/TSC2 expression, thereby activating the pathway. This suggests a mechanism of 
resistance to CDK4/6 inhibition in activating mTOR. Activation of mTOR explains the 
observation that cells treated with CDK4/6 inhibitors show aberrant cell size growth 
(Franco et al., 2016; Franco et al., 2014; Witkiewicz et al., 2015a). In fact, Franco et al. 
report that while MEK and CDK4/6 co-inhibition leads to cell cycle exit in pancreatic 
cancer, co-inhibition of mTOR and CDK4/6 results in superior activity by suppressing cell 
growth and metabolism, leading to apoptosis reduction in tumor growth (Franco et al., 
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2016). This group claims that CDK4/6 inhibition elicits metabolic reprogramming by 
stimulating glycolytic and oxidative phosphorylation metabolism, increasing 
mitochondrial numbers and reactive oxygen species (ROS). 
Discovery of small molecule inhibitor MTX-211 
Chapter 3 outlined the discovery of MTX-211, a dual inhibitor of EGFR and PI3K. The 
rational design of MTX-211 was based on known binding small molecule inhibitors of 
PI3K and EGFR omipalisib and erlotinib, respectively. Omipalisib bound to PI3K is 
flipped relative to how erlotinib binds EGFR. Therefore, while sharing a common core, 
they share similarities that enabled the design and synthesis of a dual inhibitor by 
assimilating features of both. Crystallization studies confirmed the flipped binding 
orientation of MTX-211, and in vitro kinase assays show potency against PI3K and EGFR 
at 0.6 and 3.6 nM, respectively. More expansive assays studying potency against other 
family members showed that MTX-211 possesses potent inhibitor activity against 
HER2/HER4 and mTOR. 
The rationale and computational design of MTX-211 form the basis of its novelty, as it is 
the first reported highly selective inhibitor of both a tyrosine and lipid kinase.  However, it 
remains unclear which patient population would derive the greatest benefit. The utility of 
MTX-211 as a single agent is being explored in various indications that show mutation or 
overexpression of EGFR to exploit MTX-211’s ability to target EGFR-altered cancers. 
Glioblastoma, colorectal cancer, lung cancer and pancreatic cancer are a few indications 
with a significant percentage of EGFR mutant tumors, which form part of the rationale for 
the application of MTX-211. In addition to EGFR-altered cancers, PI3K mutant tumors 
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(either PIK3CA or PTEN mutations or HER overexpression) are another component of the 
development portfolio for MTX-211. 
While MTX-211 would be expected to exhibit single agent activity in a defined population 
of patients, the greater utility of MTX-211 in combination with other inhibitors is being 
investigated. Combination-based therapies increase the chance of successful treatment 
given the wide variety of regulatory feedback pathways and signal redundancy that lead to 
resistance. A prime target for a combination-based therapy is MEK, given the reports that 
have implicated MEK in resistance to HER-based therapies. 
MEK as a target for combination therapy with MTX-211 was explored in Chapter 3, and 
the rationale has been covered in Chapter 1. Briefly, ERK-induced feedback inhibition of 
EGFR is decreased upon inhibition of MEK and other MAPK pathway kinases, which 
leads to reactivation signaling through the MAPK and PI3K-AKT pathways (Corcoran et 
al., 2012; Li et al., 2008b; Lito et al., 2012; Morris et al., 2013; Nissan et al., 2013). MEK 
inhibition has also been shown to lead to increased transcription and phosphorylation of 
HER3, an activator of EGFR and HER2 and thus several different growth pathways, which 
we have shown occurs in Chapter 3 (Kitai et al., 2016; Montero-Conde et al., 2013; Sergina 
et al., 2007; Sun et al., 2014; Turke et al., 2012a). In Chapter 3, a decrease in 
phosphorylation of T669 on EGFR was seen with MEK inhibition, which confirms the 
rationale for combining MTX-211 with a MEK inhibitor, in order to target the reactivation 
of EGFR as well as PI3K. At the same time, increased phosphorylation of HER3 was also 
seen in the models tested, leading to an increase in AKT activation in response to MEK 
inhibition. This activation of AKT was also targeted by MTX-211, which led to impressive 
synergy upon co-inhibition with trametinib and MTX-211. The data shown in Chapter 3 
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therefore establish precedent for this combination therapy in colorectal cancer. On the same 
track, in addition to MEK, it is expected that MTX-211 would be comparably effective in 
combination with BRAF inhibitors, as these have led to similar relief of feedback 
inhibition. 
The ability of signal transduction pathways to inhibit proapoptotic proteins such as BAD 
has been explored (Bonni et al., 1999; Fang et al., 1999; She et al., 2005). EGFR and PI3K 
signaling were shown to contribute to the phosphorylation of BAD on Ser112 and Ser136, 
respectively. Increased signaling through these growth pathways in cancer therefore 
prevents initiation of apoptosis (Chen et al., 2001; Mebratu and Tesfaigzi, 2009; Roskoski, 
2012; Will et al., 2014). MTX-211 inhibits both phosphorylation sites through MAPK and 
PI3K pathway inhibition, which accounts in part for increased apoptosis observed in cells 
treated with MTX-211. This agent, both as a single agent and in combination with a MEK 
inhibitor causes significant induction of apoptosis through the loss of S112/S136 
phosphorylation on BAD and induction of cleaved PARP and caspase-3 expression, 
consistent with an increase in the population of stained cells that are PI-/Annexin V+ and 
PI+/Annexin V+ (Chapter 3). The primary mechanism by which MTX-211 contributes to 
tumor growth inhibition appears to be through induction of apoptosis, by itself and in 
combination with MEK inhibition. The extent of this effect in tumors as a single agent and 
in combination is likely mutation dependent, as the activity of MTX-211 decreases in the 
presence of RAS or RAF mutations, necessitating the addition of a MEK inhibitor. 
In addition to the inhibition of EGFR and PI3K by MTX-211, some activity is observed in 
the inhibition of mTOR. This is favorable considering that inhibition of AKT activation 
has been shown affect regulatory feedback loops surrounding MTORC1 (Chandarlapaty et 
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al., 2011). Inhibition of AKT causes upregulation of a specific set of RTKs (HER3, IGF-
1R, insulin receptor) in a wide spectrum of tumor types in response to typical PI3K 
inhibitors. The ability of MTX-211 to inhibit mTOR therefore adds an additional layer 
protecting against tumor adaption to drug treatment. 
Colorectal Cancer and Pancreatic Cancer 
MTX-211 was evaluated for activity against a panel of 60 standardized cell lines curated 
by the NCI (NCI-60), of various tissue origins. However, the panel is not exhaustive for 
all tissues. The data showed that colorectal was, on average, the most responsive tissue of 
origin. As mentioned in Chapter 1, the predominance of KRAS and BRAF mutations in 
colorectal cancer and the introduction of novel therapies that preclude MAPK-altered, 
metastatic patients from receiving recently approved EGFR inhibitors introduces the need 
for novel therapies for these patients. This was the rationale for the application of MTX-
211 in colorectal cancer. 
While the majority of work done so far has been performed in colorectal cancer models, 
MTX-211 also shows promise in pancreatic cancer in early studies. As previously 
mentioned, erlotinib was recently approved for the treatment of pancreatic cancer in 
combination with gemcitabine (Amanam and Chung, 2018). Despite only modest 
improvements in outcome, the requirement for novel therapies is critical. MTX-211 was in 
part designed after erlotinib, which provides some support for the application of MTX-211 
in pancreatic cancer. Unpublished work I’ve performed in pancreatic cancer primary 
models showed an average IC50 of around 5 µM, which is in the middle of the therapeutic 
range of MTX-211 in colorectal cancer. These data are promising and are being 
investigated further to establish a potential role in treating pancreatic cancer. 
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Future Directions 
Expanding upon the findings summarized in Chapter 2, establishing the roles of caveolin-
1 and Pdcd4 in the degradation of COX-2 will be critical going forward. Elucidation of the 
mechanistic role that these proteins play in a KRASmt/CDKN2A null background will be 
enlightening. Further strengthening of the data presented with a larger panel of pancreatic 
cancer models will be required to conclusively decipher the role of COX-2 as a prognostic 
biomarker of response. It is currently unknown if COX-2 is an indication of another feature, 
such as an expressed marker of pancreatic adenosquamous carcinoma histology exhibited 
by the top two responders. Along these same lines, histology is considered less accurate by 
some who favor gene profiling as a more accurate representation of subpopulation of 
cancers. Reports have shown the power of molecular subtypes. Collisson et al. divide 
pancreatic cancer into classical, quasimesenchymal and exocrine-like (Collisson et al., 
2011). Bailey et al. divides them into squamous, pancreatic progenitor, immunogenic and 
aberrantly differentiated endocrine exocrine (Bailey et al., 2016). Moffitt et al. divide them 
based on stromal characteristics into basal-like, normal and activated stromal subtypes 
(Moffitt et al., 2015). While there may be common ground between these various 
classifications, the field of molecular subtyping of pancreatic is growing, and establishing 
the responder models into a molecular subtype may be informative and enable the 
discovery of additional responder models. 
Expanding upon the findings described in Chapter 3, further work with MTX-211 in 
colorectal cancer should focus on discovery of prognostic biomarkers. Mechanistic studies 
have shown conclusively the potential for this compound, but it remains to be determined 
where best to employ it. Precision medicine has become much more focused on similar 
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features between responders rather than a gross anatomical location. Elucidation of a 
molecular subtype or prognostic biomarker will be important in establishing a niche for 
MTX-211. Furthermore, MTX-211 showed activity in pancreatic cancer and could 
possibly be applied to many other subtypes of cancer, such as lung and neurological cancers 
which exhibit overexpression of EGFR or KRAS activation. 
Ending thoughts 
In this dissertation, the lack of treatment options for KRAS mutant disease has been 
addressed by exploring potential new therapies. Chapters 2 and 3 focused on developing 
novel therapies for the treatment of KRASmt pancreatic and colorectal cancers, 
respectively. In pancreatic cancer (Chapter 2), focus was placed on developing a novel 
combination therapy that leverages the mutation profile of pancreatic cancer through the 
inhibition of MEK and CDK4/6, targeting KRAS and CDKN2A mutations. In colorectal 
cancer (Chapter 3), instead of developing a therapy based on approved agents in 
combination, a project delineating the discovery process of MTX-211, a dual inhibitor of 
EGFR and PI3K in a single molecule, was described. While it is known that utility exists 
for kinase inhibitors in the clinic, the ideal indication for these agents needs to be optimal 
as resistance occurs rapidly. The chapters presented were based in part on the knowledge 
of existing kinase inhibitors and their lack of durable anti-tumor activity as single agents. 
The results of previous preclinical and clinical studies guided the rational design of novel 
combination therapies presented here that overcome adaptive signaling and increase 
activity in tandem. 
There are a number of pharmaceutically attractive agents that have failed in monotherapy 
trials. Looking forward, the design of rational combination approaches that build upon the 
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knowledge gained from these failed trials is imperative. The reports outlined in Chapters 2 
and 3 approach the problem in this manner. They leverage both recently approved drugs 
and knowledge from failed clinical trials to design novel polypharmacology approaches to 
treat cancer. 
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